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Abstract 
The Baculovirus Expression Vector System (BEVS) has been widely used to produce 
recombinant proteins, especially for complex biopharmaceuticals. In recent years, the insect-
baculovirus system has proved its value as a robust production platform. In this regard, 
multiple vaccines have been commercialized such as FluBlok® using this system. The work 
presented here aims to further explore their use on the production of influenza virus-like 
particles (VLPs). The goal is to successfully produce fluorescent influenza particles that 
behave similarly to native particles and that allow the purification of viral particles. 
Four different genetic constructs were investigated for the expression of dual-
fluorescent influenza VLP. Individual influenza genes were fused to different fluorescent 
proteins. Hemagglutinin was fused with enhanced green fluorescent protein (GFP), whereas, 
M1 was fused to a red fluorescent protein (RFP). The use of monomeric or multimeric RFP 
was studied, as well as, the fusion site to M1. HA-GFP was placed under the baculovirus p10 
promoter, while M1-RFP was under the control of the baculovirus polh promoter. Sf9 cells 
were used to generate baculovirus vectors that were later used to infect Sf9 cells and produce 
the influenza VLPs. Flow cytometry and confocal microcopy were used to detect individual 
levels of influenza proteins and their localization. within the cell. A proposed downstream 
process consisting of a 2-step concentration procedure and a density gradient purification for 
influenza VLPs was evaluated by tracking HA activity and baculovirus presence. Purification 
of VLPs and baculovirus was achieved by using iodixanol and sucrose density gradients, an 
undesirable result since baculovirus is the main contaminant produced in the production 
process. Further sample analysis of purified fluorescent particles was performed by flow 
cytometry. 
Our findings showed that recombinant baculovirus driving the expression of M1 
fusions, with either monomeric or tetrameric RFP, in the 3’ site presented red fluorescence 
localized at the center of the cell. The same behavior was observed when a monomeric RFP 
was fused at the 5’ site. Further purification of fluorescent VLP constructs showed lower HA 
activity of fluorescent constructs when compared with a non-fluorescent VLPs. Moreover, 
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similar migration patterns were obtained via sucrose density gradient. However, the need to 
add more purification procedures such as ion exchange chromatography are needed to fully 
isolate influenza VLP particles.  Lastly, a flow cytometry protocol to study purified particles 
was evaluated. Nano-sized fluorescent particles were detected in purified samples, which 
increased particle counts in samples with higher concentrations of HA activity and baculovirus. 
However, our analysis detected mainly coincidental events. Single particle events overlapped 
with signal noise, therefore an increase in the inherent fluorescent of viral particle should be 
explored to differentiate single particles from signal noise.    
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Every year biopharmaceutical companies manufacture millions of doses of influenza 
vaccines to protect the population against the virus. Influenza vaccine manufacturing is a 
process that is performed yearly due to the high rate of mutations in the virus. The rapid 
evolution of the virus is a major concern due to social and economic consequences that may 
be caused by the illness associated with virus infection (Dawood et al., 2017; Mao, Yang, Qiu, 
& Yang, 2012). In order to keep track of the virus mutations the World Health Organization 
(WHO) performs a worldwide screening to detect the circulating strains. The WHO then 
reports twice per year so that manufacturers can produce the most appropriate vaccine. 
Currently, the use of egg-based technology is still predominant for influenza vaccine 
manufacturing. This technology was developed during the last century and even though it has 
been optimized, is still labor-intensive and time-consuming.  This is worrisome, especially in 
pandemic scenarios where accelerated manufacturing processes are needed. To meet the needs 
of the market and emergency cases, different manufacturing processes have been assessed as 
an alternative to increase vaccine production while reducing processing time (Wong & Webby, 
2013). 
Vaccine manufacturing using insect cells is a promising alternative, especially when 
used in combination with the Baculovirus Expression Vector System (BEVS) (Kollewe & 
Vilcinskas, 2013). This expression system has been widely used for the production of complex 
biopharmaceuticals since it is easy to handle, capable of post-translational modification and 
able to produce high protein expression via infection (Peixoto, Sousa, Silva, Carrondo, & 
Alves, 2007; Young et al., 2015). An example of commercially available products using this 
expression system is Cervarix™ (GSK), developed against human papillomavirus (HPV), and 
Flublok ™ (Protein Science), a trivalent influenza vaccine. Furthermore, previous works have 
shown the capacities of insect cells to produce influenza virus-like particles (VLPs), which are 
particles mimicking the structure of influenza viral particles (Krammer et al., 2010; Thompson 
et al., 2015). Bright and collaborators (2007) showed that VLP vaccines injected to mice had 
sera producing higher inhibition of hemagglutination activity. Their results exhibited that 
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inhibit 4 isolates of a H3N2 strain were inhibit efficently, whereas, whole inactivated virus or 
recombinant HA vaccines inhibit only 2 isolates. 
The development of alternative methodologies for influenza vaccine production also 
generates the need for new analytical techniques to assess the quality, potency, and 
homogeneity of the final product. It has been mentioned that analytical technologies used for 
in ovo production can be implemented for new generations of vaccines (Thompson, Petiot, 
Lennaertz, Henry, & Kamen, 2013), however, the development of  specialized techniques 
based on inherent features of new vaccine candidates is still needed.  
Flow cytometry has been widely used as a technique for the assessment of multiple 
properties of cells and small particles (Gaudin & Barteneva, 2015). The technique has been 
previously used to characterize different baculovirus promoters driving recombinant protein 
production in insect cells after infection (George, Jauhar, Mackenzie, Kieβlich, & Aucoin, 
2015). Moreover, George & Aucoin (2015) have fused the hemagglutinin and matrix protein 
influenza proteins to fluorescent proteins to produce and study the assembly process of 
influenza VLP particles. As shown by George (2016), the latter strategy resulted in a limited 
amount of synthesized proteins being released from the cell. More specifically, M1 clustered 
in the center of the cell. Based on this work, new genetic constructs were evaluated in this 
thesis to further explore the assembly process of fluorescent VLPs. Here flow cytometry is 
used to monitor influenza VLP production in insect cells, as well as VLP purification.  
1.1 Purpose of the work 
The main goal of this work is to characterize formation of dual-fluorescent VLPs, so 
that VLP can be used as a tool to develop VLP purification protocols. 
1.1.1 Hypothesis 
Fluorescent VLPs can be used as a tool for process development; however, the yield of 
fluorescent VLPs is significantly reduced because M1-RFP is believed to be trapped in the 
nucleus. By examining different versions of fluorescent M1 fusions, it may be possible to alleviate 
problems in VLP formation and gain a novel tool for process development. 
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1.1.2 Aims and objectives 
This work can be broken down into two aims, each with their own objectives. The first aim is 
to evaluate the M1-RFP fusion, and has 3 objectives: 
1. determine the effect of red fluorescent proteins fused to the M1 gene in different 
locations; 
2. determine the effect of monomeric vs tetrameric red fluorescent proteins for M1 
fusions; 
3. determine indirectly protein expression of individual influenza genes based on 
fluorescence. 
The second aim is to use flow cytometry to detect VLPs during the purification procedures. 
The objective for this aim is to develop a protocol that can detect nano-sized fluorescent 
particles without the use of particle labelling steps. 
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Chapter 2 
Literature Review 
2.1 Influenza virus 
2.1.1 Characteristics 
Influenza is an acute respiratory disease that causes multiple symptoms such as severe 
malaise, fever, dry coughing, headache, muscle and joint pain, and runny nose (WHO, 2016). 
According to the World Health Organization (WHO) influenza virus causes about 3 to 5 
million cases of severe disease, and around 250 000 to 500 000 deaths annually (WHO, 2016).  
Pneumonia is the most common influenza-associated complication; nevertheless, organs other 
than lungs can be affected. To prevent the disease, vaccination is recommended, especially for 
high risk individuals (pregnant women, children, the elderly, health-care workers, and 
individuals with specific medical conditions).  
The influenza virus belongs to the Orthomyxoviridae family which are negative sense, 
single stranded RNA viruses. There are three types of influenza viruses: A, B and C. Type A 
and B share similar features genetically and morphologically, but they also have differences.  
The former is characterized for its broad host spectrum: humans, birds, whales, pigs, and 
horses; while the latter has only been found in humans and seals. Lastly, type C is predominant 
in humans, but it has been isolated from swine as well. All types of influenza are able to infect 
humans, however, type A has been responsible for multiple influenza pandemics (Cheung & 






  5 
Table 1 General information on influenza A virus. Modified from (Kiselev, 2010) 
 
Influenza A Virus 
Family Orthomyxoviridae 










Structure and length of   
genome 





I 2341 PB2 
 
Component of vRNA polymerase: It is an important 












Involved in apoptosis and causes significant delay in 
the clearance of influenza virus by the host immune 
system 
III 2233 PA Component of vRNA polymerase: endonuclease.  
IV 1778 
 
HA Responsible for the binding of viral particles to sialic 
acid containing receptors on the cell surface. 
V 1565 
 
NP Encapsulates the viral RNA genome. NP also helps to 
stabilize the viral genome and regulates the synthesis 
and replicative transcription. 
VI 1413 
 
NA Cleaves the cellular sialic acid residues that link the 







Major component of the virion. It helps assemble viral 
proteins and drives viral budding. 
M2 
 
Small transmembrane protein (ion channel) responsible 










Regulates a viral gene expression involved in RNA 
splicing and translation. 
NS2 (NEP) Responsible for export of nascent ribonucleoprotein 
from nucleus to the cytoplasm 
Subtype of influenza A virus 
(Characterized by the type of 
HA and NA surface 
glycoproteins) 
-HA includes 18 different types (H1- 
H18)   (Tong et al., 2013) 
-NA includes 10 different types (N1-
N11) (Tong et al., 2013)  
 
Subtypes that have been documented to infect humans 
(H1N1, H2N2, H3N2, H5N1, H7N7, and H9N2) 




Antigenic drift Minor mutation caused by the lack of proofreading mechanism of the 
viral RNA polymerase 
Antigenic shift Genetic reassortment of at least two different influenza viruses that 
infect the same cell. 
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Influenza virus contains eight viral RNA segments encoding 11 genes, a mixture of 
structural and non-structural proteins (see Figure 1). The genes that belong to the former group 
are mainly involved in structural roles and include hemagglutinin (HA), neuraminidase (NA), 
nucleoprotein (NP), matrix protein 1 and 2 (M1 and M2). HA, NA and M2 are surface proteins 
that are embedded in the lipid envelope derived from the host cell. HA is a homotrimeric 
glycoprotein responsible for cell attachment and cell entry via interaction with the sialic acid 
located on the cell membrane (Nicholls, Lai, & Garcia, 2012). Moreover, HA is synthesized 
as a precursor, HA0, which possess two subunits,  HA1 and HA2, that are exposed as a result 
of  cleaving HA0 by endogenous proteins (Gamblin & Skehel, 2010). The other main surface 
glycoprotein is NA, a homotetrameric protein which has a major role in the release of viral 
progeny by dissociating receptors on the protein membrane. This is possible by hydrolyzing 
the sialic acid from the glycoproteins (Gamblin & Skehel, 2010). Lastly, M2 is a 
homotetrameric ion channel located within the viral envelope which allows the acidification 
of the interior of the particle, causing conformational changes during the infection cycle. In 
addition, M1 is the major structural component located underneath the lipid envelop, playing 
a major role on virus morphology (Bourmakina & García-Sastre, 2003). Non-structural 
proteins consist of polymerase subunits (PB1, PB2 and PA), and the non-structural proteins 
(NS1 and NS2), participate on viral replication processes.  
Influenza A virus has subtypes based on antigenic variations of surface glycoproteins: 
hemagglutinin (HA) and neuraminidase (NA). Currently, 18 HA and 11 NA subtypes have 
been identified (Tong et al., 2013). Most of the variants circulate in non-human hosts such as 
bats, birds, swine and other mammals (Short et al., 2015). Only the subtypes A/H1N1, A/H2N2 
and A/H3N2 are known to spread commonly in humans (Petrova & Russell, 2017); however, 
cases of zoonotic transmission have been documented (de Wit et al., 2010; Kandeel et al., 
2010; RahimiRad, Alizadeh, Alizadeh, & Hosseini, 2016), increasing the possibility of a 
pandemic strain, creating a major health concern.  
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 Figure 1 Influenza virus morphology 
 
Influenza possess a high evolution rate due to two evolutionary characteristics of the 
virus: its ability to undergo antigenic drift and antigenic shift. The former refers to minor 
nucleotide mutations that occur because the viral RNA polymerase lacks a proofreading 
mechanism. Surface glycoproteins show the highest rate of nucleotide substitution, happening 
approximately 6.7 x 103 times per year for HA and 3.2 x 103 times per year for NA (Smith & 
Palese, 1989). This causes small changes to the surface proteins leading to an ineffectiveness 
of previously acquired immune protection. Antigenic shift relates to a phenomenon called 
genetic reassortment, a process involving the exchange of genomic segments of two or more 
viruses. This process occurs when multiple viruses infect the same cell and their genetic 
material is combined during the replication cycle (Landolt & Olsen, 2007).  
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2.1.2 Influenza morphology 
Influenza virus A is a pleomorphic, enveloped virus with multiple shapes from 
spherical to filamentous (Calder, Wasilewski, Berriman, & Rosenthal, 2010), ranging from 80 
to 120 nm. Viral morphology is influenced by replication cycles, viral factors and host factors. 
One factor that determines their morphology is the number of replication cycles. Chu, Dawson, 
& Elford (2018) found that fresh samples from patients contain a substantial presence of 
filamentous virus. The morphology changes to mostly spherical shape after multiple passages 
in eggs or tissue cultures (Choppin, Murphy, & Tamm, 1960). Moreover, morphology is 
determined also by genetic factors that are specific for each strain.  Bourmakina & García-
Sastre (2003) used reverse genetics to study the genetic factors influencing filamentous 
morphology in primary virus isolates. The experiment showed how transferring the M 
segment, coding M1 and M2 of the influenza A/Udorn/72 (H3N2), a filamentous strain, into 
influenza A/WSN/33 (H1N1) virus, a spherical strain, changes the phenotype, from spherical 
to filamentous. Further analysis showed the critical role of M1 in the morphology of influenza 
A virus. Similar results were found by Elleman & Barclay (2004). 
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2.2 Influenza vaccine: manufacturing process 
2.2.1 Vaccine production 
Every year a surveillance network headed by the WHO screens for new variations of 
influenza virus in humans and animals, especially in birds and pigs. Samples from patients 
with influenza-like symptoms are sent and analyzed by one of the National Influenza Centers 
spread worldwide. Once the virus is isolated, it is sent for characterization to the Collaborating 
Centers for Influenza Reference where the strain is identified and released as the recommended 
vaccine formulation for manufactures. This information is available twice per year in February 
and September, and informs on two influenza type A strains and one type B strain circulating 
worldwide (Gerdil, 2003). Once this information is released a new A type hybrid strain is 
generated by coinfecting an egg with one of the suggested strains and a high-growth strain 
which possesses an accepted safety profile, e.g. A/Puerto Rico/8/1934. This hybrid must 
express the HA and NA from the desired strain while retaining an ability to be propagated. 
Subsequently, the new sample is sequenced and confirmed before scale-up and manufacturing. 
The predominant technology used to manufacture influenza vaccine is in ovo 
production. This technology was developed during the 1940s (Goodpasture, Woodruff, & 
Buddingh, 1932; Woodruff & Goodpasture, 1931) and is a standardized and established 
process. There are three types of products that are made using this technology: whole-virus, 
split-virus and subunits vaccines. In all the cases the raw material is the allantonic fluid 
recovered from the eggs previously used to propagate the virus. Whole-virus vaccines are 
produced by chemically inactivating the virus and purifying the sample to remove protein 
contaminants. Split-virus vaccines are prepared by using a detergent treatment to dissociate the 
viral lipid membrane exposing viral proteins and subviral elements (Duxbury, Hampson, & 
Sievers, 1968). Lastly, subunit vaccines use purified hemagglutinin and neuraminidase from 
the lipid complex, along with non-protective elements (Bachmayer, Liehl, & Schmidt, 1976; 
Brady & Furminger, 1976a, 1976b). Even though egg-based technology has been used for over 
60 years and improvements have been done to the purification process and high-yield 
reassortant strains, there are significant drawbacks that must be addressed. The long 
manufacturing process and the limited manufacturing capacity due to the availability of high 
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quality eggs are the main concerns, especially when considering a pandemic scenario (Ulmer, 
Valley, & Rappuoli, 2006).   
2.2.2 New influenza vaccine technologies 
The development of alternative processes to produce influenza vaccine has been 
discussed extensively (Houser & Subbarao, 2015; Krammer & Palese, 2015). The main 
objective is to establish a process to overcomes the drawbacks of egg-based technology. Many 
approaches have been studied, offering different benefits. Some alternatives are discussed 
briefly in the following sections. 
2.2.2.1 Cell culture 
Cell-based production technologies possess greater scalability compared with egg-
based technology. Moreover, advantages such as faster production cycles, process control, and 
avoidance of egg components, that could cause allergic reactions, are possible (Milian & 
Kamen, 2015). Some of the mammalian cell lines that have been proposed as candidates for 
influenza vaccine production are PER.C6® (Koudstaal et al., 2009; Pau et al., 2001), monkey 
kidney cells (Vero) (Kistner et al., 1998; Youil et al., 2004), Madin Darbin Canine Kidney 
(MDCK) (Youil et al., 2004) and human embryonic kidney 293 cell line (HEK- 293) (Le Ru 
et al., 2010). Furthermore, replication optimization of influenza A virus  has been done by 
screening random mutations on the PR8 influenza strain to obtain a high yield strain for MDCK 
and Vero cells (Ping et al., 2015). Some of the commercially available seasonal trivalent 
vaccines using this approach are Optaflu® (Novartis, licensed in EU), Flucelvax® (Novartis, 
licensed in US), and Preflucel® (Baxter, licensed in EU). Furthermore, monovalent versions 
have also been produced Celtura® (Novartis) and Celvapan ® (Baxter). Moreover, the use of 
cell culture is not limited to mammalian cell lines, FluBlok® is a recombinant trivalent HA 
vaccine produced in insect cells using the baculovirus expression system. Unlike the 
mammalian cell lines replicating the influenza virus, FluBlok® relies on the expression and 
purification of the HA protein. 
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2.2.2.2 Universal vaccine 
The search for a ‘universal vaccine’ capable of protecting a population against a 
broader spectrum of strains instead of a narrow group is on-going. The idea relies on the 
capacity to understand virus evolution using deep-gene-sequencing and structural biology. 
These studies have the ability to characterize viral changes more efficiently and to comprehend 
how these mutations affect function, antigenicity and immunogenicity of specific proteins, HA 
for example (Erbelding et al., 2018). On this matter, some researchers have studied the stalk 
domain of the HA, a more conserved domain compared to the globular head of the protein, as 
candidate for a universal vaccine. In 2010, Steel and collaborators showed that sera from mice 
vaccinated with the stalk domain of HA, generated from the complete HA2 polypeptide and 
sections from HA1 involved in the stalk region, and lacking the globular head, possessed 
greater ELISA activity against heterologous strains compared with mice vaccinated with full 
length HA. More improvements have been developed since then, mainly focusing on 
increasing the spectrum of protection by creating chimeric HA proteins from different HA 
groups (Krammer & Palese, 2013; I Margine et al., 2013) .  
2.2.2.3 Virus-like particles (VLPs) 
VLPs are nanoscale particles that resemble a native virus structure but does not contain 
genomic material, thus disabling viral replication. In addition, increased immune response is 
expected since viral attenuation or inactivation is not required, processes than can modify 
protein epitopes and decrease the resemblance between native and vaccine virus (Roldão, 
Mellado, Castilho, Carrondo, & Alves, 2010). VLP production is achieved by expressing one 
or more structural viral proteins (see Figure 2). Several genetic constructions have been used 
to produce influenza VLPs, usually a combination of structural proteins involving M1 and at 
least one surface protein. Pushko and collaborators (2005) showed the production of a VLP 
containing M1, NA and HA using insect cells. Functional influenza VLPs, similar in size to 
native virus, were released to the media and displaying hemagglutinin and neuraminidase 
activity were obtained. Further experiments revealed that VLPs were able to elicit serum 
antibodies and inhibit viral replication in mice. Another experiment performed by Wu et al. 
(2010) showed the production of influenza VLPs in Vero cells by expressing the proteins M1, 
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NA, HA and M2 . These particles were also able to elicit an immune response, fully protecting 
mice against lethal infection. Influenza VLPs expressed in insect cells have shown a broader 
immune response compared to whole inactivated virus or recombinant HA vaccines (Bright et 
al., 2007). Bright and collaborators (2007) showed that mice vaccinated with H3N2 influenza 
VLPs produced in insect cells, had sera that inhibited hemagglutination for 4 different 
influenza isolates. On the other hand, mice vaccinated with either whole inactivated virus 
vaccines or recombinant HA vaccines were less effective eliciting hemagglutination inhibition.  
Moreover, the expression system of choice plays an important role on VLP production. 
Different production methodologies are needed according to each system, changing upstream 
and downstream processing. Different production platforms have been used to achieve 
functional influenza particles such as HEK293 (Thompson et al., 2015), insect cells  (Sf9 and 
Sf21) (Krammer et al., 2010; G. E. Smith et al., 2013; Thompson et al., 2015), Nicotiana 
benthamiana (Makarkov et al., 2017; Pillet et al., 2016) and Vero cells (Pushko et al., 2005). 
 
 
Figure 2. Comparison of influenza and influenza VLP. A) Influenza virion and B) influenza VLP 
assembled by HA, NA, M1 and M2 influenza proteins   
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2.3 Insect cells 
Insect cell technology is a versatile platform to produce recombinant proteins. Insect 
cells have the ability to produce complex proteins requiring post-translational modifications, 
are easy to manipulate, and can produce high yields via viral infection (Kollewe & Vilcinskas, 
2013). Table 2 compares insect cells with other expression systems commonly used. As 
eukaryotic cells, post-translational modifications are possible, allowing in most cases the 
proper processing with respect to disulfide linkage, phosphorylation, fatty acid acylation and 
glycosylation (Becker-Pauly & Stöcker, 2011). Nevertheless, the glycosylation processing 
differs from other species. Glycosylation reactions taking place in the endoplasmic reticulum 
are highly conserved among eukaryotes, while the reaction in the Golgi complex are species 
specific and cell type specific. Insect cells have less complex N- and O- glycosylation, causing 
shorter sugars to be attached to the protein (Callewaert, 2009).  
Table 2 Comparison of different expression systems. Modified from  



















++ ++ +++ - + 
Homogeneity of N-
glycans 
++ ++ + Not 
relevant 
- 
Biological activity ++ ++ +++ + ++ 
Immunogenicity +++ +++ +++ + ++ 
Production levels + ++ + +++ +++ 
Safety concerns ++ ++ + +++ +++ 
Downstream 
processing efforts 
++ + ++ ++ ++ 
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Sf9 cells (derived from Spodoptera frugiperda) and High Five™ (derived from BTI-
TN5B1-4) are the most studied insect cell lines for the production of complex biologics 
(Krammer et al., 2010). Three main approaches are used to produce recombinant proteins in 
insect cells: transient expression (Chang et al, 2018; Shen, Hacker, Baldi, & Wurm, 2013), 
generation of stable cell lines (Pfeifer, 1998) and viral infection using a baculovirus expression 
vector (BEV) (J.-P. Yang, 2016). A comparison of these approaches is shown in Table 3. 
These approaches are not mutually exclusive; there are reports showing production of complex 
biologics, e.g. VLPs, using a stable cell line coupled with baculovirus infection (Sequeira et 
al., 2017). 
Table 3. Comparison of different recombinant expression strategies used for production of complex 
biologics in insect cells. 
Baculovirus Expression Vector 
System (BEVS) 
Transient expression Stable Cell line 
Advantages Disadvantages Advantages Disadvantages Advantages Disadvantages 
-Commercial kits 
available 






















-Variation due to 
random integration 
 
2.3.1 Baculovirus: classification and infection cycle 
The Baculoviridae is a family of viruses capable of infecting lepidopteran cells. Their 
genetic information is contained in a circular, doubled stranded DNA genome between 80-180 
kb. The morphology of budded virus is an oval-like shaped enveloped particle with a diameter 
sizing from 30-60 nm and approximated width of 250-300 nm. Based on morphology the 
family is divided in two groups: nuclear polyhedrosis viruses (NPVs) and granulosis viruses. 
One of the commonly used NPVs in research and industry is the model organism Autographa 
californica multicapsid nucleopolyhedrovirus (AcMNPV) (Theilmann et al, 2005).  
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The lytic infection cycle of AcMNPV is divided into four temporal phases: immediate 
early, delayed-early, late and very late (Figure 3). The early phase of infection starts when the 
virus enters in the cell via endocytosis (Dong et al., 2010). Once in the nucleus, the virion 
releases their genetic material, initiating DNA transcription. During the early stages RNA is 
produced by host RNA polymerase II. Following the early phase, virus transcription transitions 
from using the host RNA polymerase II to using a viral polymerase leading to transcription of 
late and very late genes. The late phase of infection takes place starting at 6 hours post 
infection, whereas the expression of very late genes is active 20 hours post infection 
(Theilmann et al, 2005).  
 
Figure 3 Baculovirus replication cycle. Winding arrows emphasize the overlap events on the 
baculovirus replication cycle. Modified from Rohrmann (1992).  
 
As a result of the infection, two types of virions are produced: budded virus (BV) and 
occlusion-derived virus (ODV). Even though they share the same genetic information, they 
differ in structural proteins, in morphology (Figure 4), cellular site maturation, time of 
maturation, source of viral envelopes, antigenicity and infectivity (Kelly et al, 2007). The 
former is produced by budding out the cell during early stages of the infection and allow cell 
to cell infection (Volkman & Summers, 1977). The latter is produced during late stages of 
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infection, primarily in the nucleus and is surrounded with polyhedral proteins. This protein 
layer increases particle stability outside the host insect. Typically, BV are used to infect insect 
cell lines for commercial and research purposes, genetic constructs normally choose promoters 
that are active during the late phase of infection, when ODV are formed. Polyhedrin and p10 
are structural proteins that are produced in large amounts during the late phase of infection.  
This is due to the high level of gene expression structural proteins (polyhedrin and p10) 
occurring during the late phase of infection. Moreover, ODV are capable of infecting midgut 
epithelial cells up to 10,000- fold more efficiently than BVs, while BVs are able to infect cell 
cultures 1,000-fold more efficient compared with ODVs (Volkman, Summers, & Hsieh, 1976; 
Volkman & Summers, 1977). Therefore, the biotechnology industry mainly uses BV in their 
processes instead of ODV.  
 
 
Figure 4 Baculovirus morphology.  
2.3.2 Baculovirus Expression Vector System (BEVS): production strategies 
Baculovirus Expression Vector System (BEVS) is a platform that involves the use of a 
plasmid, a baculovirus vector and an insect host cell line (Hitchman et al. 2011). The 
technology is based on the baculovirus capacity to use the host protein processing machinery 
to express a protein of interest. This methodology allows easy manipulation, large DNA 
carrying capacity and production of high viral titers (Airenne et al, 2013). The first BEVS 
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developed by Smith and collaborators (1983) was designed to express human beta interferon 
integrating the gene under the control of the polyhedrin promoter, active during the very late 
stage of the process.  Further experiments performed by Licari and Bailey (1991) showed the 
importance of multiplicity of infection (MOI) and time of infection (TOI) during expression 
of β-galactosidase under the control of the polyhedrin promoter using Sf9 cells. MOI is a 
parameter that relates the number of plaque forming units (PFU) added to a specific amount of 
cells at the time of infection. Their results showed that increasing the MOI while infecting cells 
during the late exponential phase of growth leads to a logarithmic relationship between final 
β-galactosidase production and MOI. In contrast, if the infection takes place in the early 
exponential phase, the concentration of final product is reduced if the MOI is greater than 1. 
The complexity of the system demonstrates that recombinant protein production in insect cells 
is not trivial. 
Moreover, insect cell technology is known for their capacity to produce complex and 
multimeric proteins, which in some cases involves the expression of more than one gene at a 
time. Strategies to address these requirements are co-infection or co-expression. The former 
involves the use of multiple recombinant baculovirus, each one carrying a single gene 
(monocistronic) to infect a cell culture, while the latter relies on a single recombinant 
baculovirus carrying multiple genes (polycistronic). Combinatorial experiments using co-
infection strategies with poli- and monocistronic baculoviruses have shown that the ratio of 
each recombinant baculovirus added affects the yield of complex biologics (Aucoin, Perrier, 
& Kamen, 2006). Usually, promoters such as p10 and polh, activated during the very late stage 
of infection, are chosen when designing genetic constructs to drive gene expression, this choice 
is due to previous experience obtaining high yield while using them, nevertheless, studies have 
shown the potential of alternative promoters activated during early, intermediate and late stages 
of infection (George et al., 2015; Lin & Jarvis, 2013; Martínez-Solís, Gómez-Sebastián, 
Escribano, Jakubowska, & Herrero, 2016). Lin and Jarvis (2013) have shown that late and very 
late promoters, p6.9 and polh, produce higher levels of RNA but lower protein levels compared 
with immediate early and delayed early promoters, ie1 and 39K, when expressing a secreted 
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alkaline phosphatase. The previous evidence reinforces the need of more complex experiments 
to fully understand the dynamics of this platform. 
2.4 Influenza VLP production in Insect cells 
The capacities of the insect platform to produce VLPs has been demonstrated, 
especially using BEVS. Co-expression (Latham & Galarza, 2001; Irina Margine, Martinez-
Gil, Chou, & Krammer, 2012) and co-infection (Krammer & Palese, 2015; Thompson et al., 
2015) strategies have shown to be able to properly produce VLPs.  Furthermore, productivity 
assessments have been performed showcasing higher productivity from insect cells compared 
with other expression systems. Thompson and collaborators (2015) compared influenza VLP 
production using BEVS with Sf9 cells and using baculovirus transduction of HEK293 cells. A 
co-infection strategy was used with Sf9 cells relying on three recombinant baculovirus, each 
one expressing either HA, NA or M1 at a MOI of 3.  The results showed that the insect cell 
system produced 35 times higher concentration of VLPs compared to HEK 293 cells. However, 
baculovirus contamination was one of the main drawbacks of the insect platform.  Krammer 
and collaborators (2010) performed a study comparing two different insect cell lines, Sf9 and 
BTI-TN5B1-4, to produce influenza VLPs. Cell cultures were co-infected with two 
recombinant baculovirus expressing either HA or M1 at a MOI of 10. The findings revealed 
that influenza VLP process in BTI-TN5B1-4 decreased the baculovirus contamination while 
increasing hemagglutination activity. More recently, Sequeira and colaborators (2017) have 
shown a modular system using a stable High Five™ cell line and baculovirus to produce 
influenza VLPs expressing multiple subtypes of HAs. The study involved the expression of 
two HA molecules by the stable cell line, whereas, infection of the cell culture was performed 
using a baculovirus driving the expression of M1 and three HA molecules. This new approach 
showcased the versatility of production strategies for the insect-BEVS platform. 
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2.5 Downstream processing of VLPs 
The purpose of downstream processing is to eliminate contaminants formed during the 
manufacturing process and to produce large volumes of concentrated product without 
disturbing their biological activity (Morenweiser, 2005). For influenza VLPs produced in 
insect cells, downstream processing is challenging. The raw product contains multiple 
contaminants such as cell debris, host protein, baculovirus and baculovirus DNA (Krammer et 
al., 2010). Baculovirus is a by-product considered the main contaminant during the process. 
This can be a concern because baculovirus has been shown to have the capacity to transduce 
human cells (Chuang et al., 2009; Kenoutis et al., 2006; Kukkonen et al., 2003) and induce 
cytokine expression causing a strong immune response (Abe et al., 2003; Hu, 2008). Avoiding 
adverse effects is critical for manufacturing companies, which is why there is a need to develop 
scalable and robust purification procedures.  
 
Figure 5. Generic VLP downstream processing. 
Purification of influenza VLPs requires several steps to reach the purity, potency and 
morphological criteria. Figure 5 shows an overview of downstream processing for VLPs. The 
first purification step is clarification: a solid-liquid separation. Given that influenza VLPs are 
released to the media, cell lysis is not required, diminishing purification complexity. 
Centrifugation and filtration are processes commonly used to separate cell debris. For a long 
time, batch or continuous centrifugation was the process of choice; however, in recent years 
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membrane processes have gained interest since they are easy to scale up and provide more 
control over operating shear stress  (Ladd & Jürgen, 2015).  During this step, cells and cell 
debris are removed from the bulk media. The next step is to concentrate VLPs while reducing 
working volume. Tangential flow filtration (TFF) has been used to concentrate VLPs in 
different occasions using membranes with different cut-offs  ranging from 750-500 kDa 
(Negrete, Pai, & Shiloach, 2014; Peixoto et al., 2007). Recently, Carvalho and collaborators  
(2016) used TFF to concentrate influenza VLPs produced in High Five™ cells using a 300 
kDa membrane cut off. 
Further purification can be achieved by different methods depending on the scale of the 
process. At laboratory scale, ultracentrifugation and density gradients are techniques that allow 
VLP purification. In combination, the aforementioned techniques can be considered a two-step 
process. First concentrating the viral samples by ultracentrifugation, with or without a cushion, 
to remove low density particles. Then, viral particle purification based on density once the 
virus is submitted to a density gradient high-speed centrifugation. This process has been widely 
used to purify influenza VLPs (Thompson et al., 2015), nevertheless baculovirus 
contamination is still one of the main issues with this technique since baculovirus share similar 
density compared to influenza (Krammer et al., 2010). Moreover, ultracentrifugation steps are 
non-scalable, tedious and labor-intensive (Vicente, Roldão, Peixoto, Carrondo, & Alves, 
2011).  In contrast, large scale processing is moving towards chromatography steps. In this 
regard, ion exchange chromatography is one of the techniques that has shown great results as 
an intermediate purification step (Sofia et al., 2017). An example was shown by Carvalho et 
al. (2016). In their research they used a Sartobind Q MA 75 anion exchange membrane to 
perform negative mode chromatography as an intermediate purification step for influenza 
VLPs purification. Similarly, the company GE Healthcare Life Sciences (2011) have shown 
that the ion exchange column Capto Q is able to isolate influenza VLPs while decreasing 
baculovirus presence and baculovirus DNA.  
Finally, a polishing step is needed to completely isolate the particle of interest. In this 
process, VLPs are transferred to the final formulation buffer while reaching the desired 
concentration to optimal dosage. Polishing of VLPs mostly involves size exclusion 
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chromatography  (SEC) (Carvalho et al., 2016), ultrafiltration/diafiltration (Hanh et al., 2013) 
and sterile filtration.  
2.6 Analytical techniques for characterization influenza VLPs produced in 
insect cells. 
Analytical techniques are used to obtain specific information during production processes 
and allow the assessment of product quality. There is no universal technique that provides all 
the quality information of a single molecule, thus, multiple methodologies are needed to fully 
characterize a specific product. Influenza vaccines have been commercially available since the 
last century, consequently there is already a workflow to characterize the virus when isolated 
directly from patients or animals, and during vaccine manufacturing. This prior knowledge has 
been transferred to evaluate new vaccine candidates facilitating quality control procedures, 
since no modifications were needed. In this section traditional and new analytical approaches 
used to characterize influenza VLP particles will be reviewed. 
Methodologies can be divided into three different classes: indirect quantification based 
on total protein, enzymatic activity, and total particle quantification. The first class provides 
information related to protein content and protein features. Colorimetric techniques such as 
Pierce BCA Protein Assay (Thermo Science, Rockford, USA) , used to determine protein content, and 
western blots are protocols that belong to this classification. Commercial kits to quantify total 
protein are not commonly used to assess VLP production due to their non-specific nature, 
whereas, western blot is frequently used as a more specific technique to detect expressed 
proteins. The second group relies on the enzymatic activity of the antigen on the VLP surface. 
Depending on the VLP design, HA or/and NA properties can be used to quantify viral particles 
indirectly. Lastly, total particle counts of VLPs is a methodology that has shown great results 
to detect VLPs in semi-pure samples. Techniques to visualize the particles from a pure or semi-
pure sample such as transmission electron microscopy (TEM) are part of this group. 
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2.6.1 Total protein concentration 
2.6.1.1 Western blot 
Western blot is a technique that allow the detection of specific proteins in a sample. The 
procedure involves protein separation based on molecular weight through sodium dodecyl sulfate–
polyacrylamide gel electrophoresis (SDS-PAGE). The separated proteins are then transferred to a 
membrane, which is incubated with labeled antibodies targeting the protein of interest. After developing 
the membrane, the presence of the target protein is seen as a band in the membrane. This technique has 
been used extensively to detect the presence of HA and M1 in influenza VLP samples (Krammer et al., 
2010; Thompson et al., 2015). This is the only technique that can detect the presence of M1 protein. 
2.6.2 Enzymatic assays 
2.6.2.1 Hemagglutination assay  
Hemagglutination assay (HA Assay) is a technique that was developed in the 1940s to 
indirectly quantify agglutination properties of the HA molecule (Hirst, 1942). The 
methodology is based on serial dilutions of a viral sample combined with red blood cells 
(RBCs). This technique has been widely used in literature to quantify influenza VLPs, 
however, there are some issues with reproducibility of results due to blood source, blood 
concentration, and decay of hemagglutination activity (HA activity) over time (Thompson et 
al., 2013). Nevertheless, there are reports showing false positives of this technique when used 
for HA quantification in the insect-baculovirus system (Yang et al., 2007). Due to the budding 
nature of the baculovirus, it has been shown that baculovirus particles are able to display the 
HA molecules on their membrane (Yang et al., 2007). 
2.6.2.2 Neuraminidase activity  
Like the HA Assay, NA enzymatic activity can be used to indirectly evaluate the 
concentration of VLPs. Multiple commercial kits are available, however, variability among 
different kits have been reported (Nayak & Reichl, 2004). A comparison among three different 
techniques to measure neuraminidase activity from influenza VLPs produced in MDCK cells 
was performed by Nayak and Reichl (2004). The activity was evaluated by thiobarbituric acid 
(TBA), a fluorometric method using Amplex Red as a fluorogen (FL-AR), and FL-MU-
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NANA. Their results showed that FL-MU-NANA is more robust, with lower limits of 
detections and lower background noise. The A-star influenza neuraminidase inhibitor 
resistance detection kit, which was used by Quan and collaborators (2012) to evaluate M1-NA 
VLPs produced in insect cells, is also possible. 
2.6.2.3 Single radial immunodiffusion (SRID) assay 
 The single radial immunodiffusion (SRID) assay is the only approved test by the WHO 
to evaluate the potency of an influenza vaccine. The technique measures the radial diffusion 
of a viral antigen in an agarose matrix containing antigen-specific antibodies. In contrast to the 
HA assay, this technique measures the amount of HA protein rather than its activity. This 
technique has been previously used to evaluate the production process of influenza VLPs in 
HEK and insect cells (Thompson et al., 2015). However, this protocol lacks robustness. The 
drawbacks of this technique include: the presence of non-aqueous components which can 
interfere with HA diffusion, long processing times, low sensitivity, a need of updated version 
of the HA antigen, as well as, their antibodies, and aggregation of HA protein at high 
concentrations (Thompson et al., 2013).  
2.6.3 Total particle counts 
2.6.3.1 Transmission electron microscopy (TEM) 
Transmission electron microscopy (TEM) is considered the gold standard when 
quantification of viruses is needed. This technique relies on visual counting of virions along 
with latex particles of known concentration to determine total viral particle concentration 
(Malenovska, 2013). Size distribution data can also be acquired by TEM, however, the process 
is labor-intensive due to visual counting performed for the assay. Thompson and collaborators 
(2015) have used this technique to quantify production of influenza VLPs and baculovirus 
contamination from HEK and insect cell platforms. The main drawbacks of the previous 
methodologies are the need of a concentrated and pure, or semi pure, sample before imaging, 
and a skilled operator doing the counting.  These factors can impact the particle quantification 
dramatically. 
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2.6.4 New technologies to track and quantify VLPs 
Ion exchange-high performance liquid chromatography (IEX-HPLC) has been used by 
Transfiguracion and collaborators (2015) to quantify influenza VLPs produced in HEK cells. 
The technique, calibrated with a sample of known titer, allows the quantification of viral 
sample by calculating the area of the peak produced when the VLPs are eluted. The new 
methodology was compared with standard techniques such as TEM, virus counter (ViroCyt) 
and TCID50 assay, showing similar titers. 
Another technique that has been proposed is nanoparticle tracking analysis (NTA). 
NTA is a new technique developed to visualize particles in suspension by a focused laser beam. 
This technique tracks the Brownian motion of each single particle, frame by frame, to obtain 
the particle hydrodynamic diameter. The concentration of particles is acquired once the 
particles are counted and related to the sample volume. More specific  details are described by 
Steppert and collaborators (2017). This method has been used to quantify total enveloped 
virus-like particles and compared with other non-traditional methods such as size-exclusion 
HPLC with UV detection (SE-UV), and detection with multi-angle light scattering (SE- 
MALS). The results showed that NTA overestimated the particle counts, especially with crude 
samples, by counting cell debris rather than VLP particles. In this regard, both SE-UV and SE-
MALS can quantify particles only after purification steps are performed. In addition, SE-UV 
needs a standard curve to calculate counts properly. On the other hand, SE-MALS does not 
require a pre-made calibration curve since the particle number is calculated based on the 
differential scattering intensity of the particles. 
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Chapter 3 
Generation and Tracking of Fluorescent Influenza Proteins in Insect 
Cells 
3.1 Chapter objective  
The use of fluorescent proteins to study influenza VLPs has previously been shown as 
a tool to monitor protein localization within the cell, mainly focusing on HA (Young et al., 
2015). Expression of influenza proteins fused with fluorescent proteins can be used as a tool 
to understand assembly and tracking of influenza VLPs in insect cells. Previously, George & 
Aucoin (2015) have shown the expression of  influenza genes fused to fluorescent proteins in 
insect cells. In their work, enhanced green fluorescent protein (GFP) was fused to HA and 
DsRed2, a red fluorescent protein, was fused at the 3’ site of the M1 protein. Their findings 
showed green expression exclusively in the cell membrane, whereas, red fluorescence was 
detected first near the center of the cell before reaching the cell membrane. Moreover, George 
(2016) results also showed that only a limited amount of synthesized proteins was released as 
influenza VLPs. 
To further explore the use of fluorescent influenza fusions, multiple genetic designs 
were tested to understand the effect of fluorescent proteins fused to influenza proteins. The 
effect of red multimeric or monomeric fluorescent protein was evaluated by comparing 
DsRed2 with mKate2, the former being an obligated tetrameric protein while the latter being 
a monomeric protein. The assessment was done while both red fluorescent proteins (RFPs) 
were fused at the 3’ end. In addition, mKate2 was fused in different sites of the M1 gene to 
identify the optimal fusion site. Here, flow cytometry and confocal microscopy are used to 
monitor the expression and localization of fluorescent influenza protein fusions in the insect-
baculovirus system. The goal of this chapter was to determine if alternative M1 fusions could 
be used to change the localization of the M1 fusion in the cell. 
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3.2 Materials and Methods 
3.2.1 Cell Culture 
Spodoptera frugiperda clonal isolate 9 (Sf9) cells were maintained in SF-900™ III 
serum-free media (GIBCO, Carlsbad, CA, USA) at 27°C on an orbital shaker (VBR, 
Champaign, Illinois, USA) rotating at 130 revolutions per minute (rpm). Cell density was 
maintained between 0.5x106 to 4 x106 cells/mL in 125mL capped glass Erlenmeyer flasks 
having a working volume of 30 mL. Cell viability of the cell culture was measured using trypan 
blue staining and was maintained above 95%. Cell counts and viability were examined using 
Countess™ II (Thermo Fisher) 
3.2.2 Baculovirus generation and amplification 
P21 stocks were generated by infecting Sf9 cells at a density of 1.5x106 cells/mL in a 
30 mL culture with a MOI of 0.1 using P1 stock. Baculovirus was harvested once the viability 
was below 70%. The infected culture was collected and centrifuged at 800 xg for 10 min, then 
filtered through a 0.2 µm membrane (VWR International, Mississauga, ON, Canada). 
Baculovirus stocks were stored at 4°C. The second passage virus stocks (P2) were quantified 
using end-point dilution assay (EPDA) and flow cytometry.  
3.2.3 Baculovirus quantification using end-point dilution assay 
Baculovirus titers were calculated by end point dilution assay. Exponential growth 
phase Sf9 cells were diluted to a concentration of 2x105 cell/mL by adding SF-900™ III serum-
free media (GIBCO, Carlsbad, CA, USA). 100 µL of cell suspension was seeded in each well 
of a 96-well plate, allowing to attach for 1 hour. Virus stocks were diluted with SF-900™ III 
serum-free media, from 10-2 to 10-10. 10 µL of dilution was added to the plated cells (each virus 
dilution being added to 12 wells). The 96-well plate was placed in a sealed plastic box 
containing a wet paper towel and incubated at 27 °C for 5-7 days. After incubation, the plate 
                                                     
1 Recombinant baculovirus is generated by transfecting insect cells with a baculovirus genome containing the 
gene of interest. After 72 hrs, budded virus is released to the media and harvested, this is known as P0 virus stock. 
To increase viral concentration a insect cell culture is infected using a low MOI to generate the P1 virus stock. 
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was examined under a fluorescence microscope, and wells were scored as infected or non-
infected based on fluorescence. Titer was calculated as detailed in Appendix A. 
3.2.4 Fluorescent VLP production 
To produce fluorescent VLPs, 100 mL of Sf9 cells at a density of 1.5x106 cells/mL 
were infected at a MOI of 5. Genetic constructs used for this study are shown in Figure 6. 
Recombinant baculovirus encoding these genetic constructions were generated by Mark 
Bruder in the Aucoin Lab. The infection was monitored by determining cell density and 
viability every 24 hours. The supernatant was harvested once the viability was around 70%, 
approximately 72 hours post-infection. The cell culture was centrifuged for 15 min at 800xg 
at room temperature. Supernatant was recovered and filtered using a 0.2 µm filter and stored 
at 4°C, whereas the cell pellet was stored at -80°C until more experiments were performed. 
 
 

















Figure 6 Genetic variants for dual-fluorescent influenza VLP and non-fluorescent VLP. Recombinant 
baculovirus containing influenza constructs were generated by Mark Bruder in the Aucoin Lab. 
 
  28 
3.2.5 Infection flow cytometry analysis 
To track the progress of infection, a sample of infected cell culture was analyzed using 
flow cytometry every 24 hours. To prepare the sample, 1 mL of infected culture was 
centrifuged at 100xg for 10 minutes and the supernatant was discarded. The cell pellet was 
resuspended using 1mL of 2% paraformaldehyde and placed in the dark at room temperature 
for 30 minutes. The sample was then transferred to a cytometer tube and diluted by adding 
4 mL of PBS. The sample was analyzed using a BD FACSCalibur (BD Biosciences, 
Mississauga, ON, Canada) at a flow rate of 60 μL/min to capture 10,000 events per sample. 
The results were acquired using CellQuest Pro (BD Biosciences, Mississauga, ON, Canada) 
and analyzed with FlowJo (Treestar Inc., Ashland, OR, United States) software. FL1 detector 
(emission 530 nm, bandpass 30nm) was used to detect green fluorescence, while FL3 detector 
(emission 670 nm, longpass) was used to detect red fluorescence. Relative particle size was 
analyzed by forward scatter (FSC) with a voltage of E1 and gain of 6.55. Granularity was 
evaluated by side scatter (SSC) setting the voltage at 300 and a gain of 1. Both, FSC and SSC, 
were set on a linear scale. In contrast, FL1 (voltage:258) and FL3 (voltage:304) used a 
logarithmic scale to acquire the data. The previous settings were maintained for all infection 
experiments. 
3.2.6 Confocal microscopy 
Confocal microscopy was performed to analyze protein location inside the cell. A 
sample of 1 mL of infected cell culture was centrifuged at 100xg for 5 min. The supernatant 
was discarded, and the pellet was washed with in 1mL of PBS. The sample was pelleted and 
fixed for 15 minutes in the dark by adding 1mL of 4% paraformaldehyde. The sample was 
washed with 1mL of PBS and stained with 4′,6-diamidino-2-phenylindole (DAPI) for 5 
minutes in the dark. Finally, the sample was pelleted and resuspended in 10uL of PBS. A drop 
of stained sample was placed on a 76.2 × 25.4 × 1 mm microscope slide and a cover slip was 
placed on top of the drop. The cover slip was sealed using paraffin wax and a cotton swab. 
Imaging was conducted on a Zeiss LSM 510 confocal microscope (Zeiss Canada, Toronto, 
ON, Canada) using a lens of 63x magnification. 
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3.3 Results  
With the aim of assessing bicistronic recombinant baculovirus driving the expression 
of fluorescent influenza fusion proteins, Sf9 cultures were infected with a MOI of 5 and the 
cell density and viability were monitored every 24 hours (Figure 7). Cells were analyzed every 
24 hours using flow cytometry and confocal microscopy to track green and red fluorescent 
signals.  
 
Figure 7. Cell density and viability of Sf9 cells infected with recombinant baculovirus producing 
influenza fluorescent fusions.  
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3.3.1 Tracking influenza proteins 
Protein localization was monitored by confocal microscopy every 24 hours (Figure 8). 
Confocal images for each variant showed green fluorescence situated at the cell membrane for 
all the variants after 24 hours post infection (hpi). Green fluorescent protein (GFP) localization 
did not change between 24 and 72 hpi. Infection using a baculovirus harboring a HA-GFP and 
a native M1 was used as an additional control (Appendix B). No changes in green fluorescent 
localization was observed. On the other hand, red fluorescence was detected at 24 hpi only for 
mKate2 variants, whereas, for the DsRed2 variant, red fluorescence was only detected after 48 
hpi. RFP localization differed depending on the fusion site chosen. Both constructs with red 
fluorescent fusions at the 3’-terminus, either monomeric or tetrameric, displayed a 
concentrated expression of RFP at the nucleus. This feature was maintained during for the all-
time points examined. The 5’ mKate2 variant behaved similarly, concentrating RFP at the 
nucleus, but it appeared not as clustered as the counterpart located at the 3-terminus constructs. 
Lastly, M mKate2 variant showed a uniform distribution of red fluorescence throughout cells. 
Furthermore, a closer analysis on individual cells showed the presence of red fluorescent 
clusters at the cell membrane (Figure 9). This observation demonstrated that M1-RFP fusions 
have the capacity to reach the cell membrane, but possibly only when M1 is disrupted.  
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 Hours post-infection (hpi) 





























   
Figure 8 Confocal images of infected Sf9 cell. Confocal microscopy was performed every 24 hours 
for each variant. Samples were fixed and stained with DAPI to recognize the cell nuclei. and imaged 
using a 63x magnification. 
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Figure 9 Single Sf9 cells infected with different baculovirus constructs at 72 hpi. The images only 
show the localization of red fluorescence inside the cells. 
3.3.2 Monitoring infection process and expression levels 
Flow cytometry was used to assess the changes in forward scatter (FSC), side scatter 
(SSC) and fluorescence intensity of Sf9 cells once the cells were infected with recombinant 
baculovirus that allow the expression of the fluorescent influenza fusion proteins. A total of 
10,000 events were acquired for each sample every 24 hours. FSC and SSC were used to 
evaluate the lytic process of the BEVS systems (Figure 10). Uninfected Sf9 cells were used to 
determine the profile of healthy cells, and this population was gated as a control (Appendix 
C). The gate was applied to the profiles acquired from each culture every 24 hours. FSC vs 
SSC plots show the formation of a new population at 48 hpi, being more distinguishable at 72 
hpi (Figure 11 A) shows the decrease of events inside the uninfected gate for all the variants 
during the infection process. Furthermore, single channel analysis was performed to determine 
the changes in SSC and FSC for gated events during the infection process. Figure 11 B and 
11 C shows an increase in mean value of SCC after 24 hpi which was maintained for 72 hours. 
The mean FSC value decreased at 24 hpi, except for 3’ mKate2 variant which increased at 48 
hpi. SSC histograms, Figure 10, for all the variants displayed a comparable tendency with only 
one peak for during the expression of fluorescent influenza fusions. Conversely, FSC profiles 
exhibit a single peak during the first 48 hours of infection, however, a new distinguishable 
peak appeared after 72 hpi. 
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 3’ DsRed2  3’ mKate2  M mKate2  5’ mKate2 
Figure 10 Flow Cytometry profiles for FSC and SSC during infection. 
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Figure 11 Analysis of infections. A) Events localized inside the uninfected gate. B) Mean FSC value 
of events inside the uninfected gate and c) Mean SSC value of events inside the uninfected gate 
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Fluorescence expression levels were monitored during infection using flow cytometry. 
The FL1 channel was used to determine GFP expression levels, whereas, FL3 was used for 
RFP. A gate containing all the fluorescent events was created to analyze the data. Figure 12 
shows the different expression profiles acquired for each fluorescent variant, as well as, single 
channel profiles of gated events. These results provide indirect expression levels of HA and 
M1 synthesis. Moreover, geometric mean fluorescent values for GFP and RFP were 
determined based on gated events (Figure 13). Low RFP signal was detected at 24 hours, 
increasing at 48 hpi. Only 5’ mKate2 presented a decay in RFP at 72 hpi. From these results, 
M mKate2 displayed the highest GFP and RFP mean values, nevertheless, analysis of GFP 
histograms (Figure 12) demonstrate that 3’ DsRed2 reaches higher intensity levels even 
though mean relative fluorescence is lower. Table 4 shows the statistics of fluorescent events 
for each variant, showing the variability of data acquired during the experiment. 
Additionally, to study the expression levels of individual genes a normalized ratio of 
GFP and RFP intensities was calculated for all the variant, (Figure 13 C). The results showed 
that in all cases GFP is produced in higher levels when compared with RFP. The mKate2 
variants showed increase in RFP signal after only 24 hpi, whereas, 3’DsRed2 variant showed 
a drop in the ratio after 72 hpi demonstrating increased RFP levels. 
Table 4 Fluorescent events statistics at 72 hours post-infection. 
 










3' DsRed2 11.1 8.79 14.4 15.6 1 2.56 4.21 5.06 
3' mKate2 2.21 4.08 6.35 7.81 1 4.62 7.75 8.96 
5' mKate2 39.2 11.5 21.3 23.2 1 2.12 4.74 9.31 
M mKate2 56.2 30.6 46.2 38 1 4.23 10.9 18.2 
Uninfected cells 1.15 1.14 1.14 n/a 1 1.01 1.01 n/a 
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 Hours post-infection (hpi) 
















































   
 
  3’ DsRed2  3’ mKate2  M mKate2  5’ mKate2 
Figure 12 Fluorescent analysis of the variant throughout the experiment. A) GFP vs RFP profiles 
showing the gated events. B) Single GFP channel distribution of gated events. C) Single RFP channel 
distribution of gated events.   
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Figure 13 Fluorescent profile analysis. A) Geometric mean Green, and. B) Geometric mean Red 
fluorescence values. C) Ratio of normalized GFP/RFP intensity levels. 
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3.4 Discussion 
This works shows the individual tracking of influenza proteins using different fusion 
partners as a tool to monitor protein expression and localization within the cell. The use of 
fluorescent proteins allows the study of temporal and spatial expression of genes by measuring 
fluorescence in live cells. These properties can also be used to study localization, dynamics of 
viral particles and expression levels (Piatkevich & Verkhusha, 2011).  
3.4.1 Tracking HA influenza protein 
Confocal microscopy was used to study the expression and localization of fluorescence. 
Expression of HA-GFP was localized at the cell membrane in all cases, which is consistent 
with the work of George & Aucoin (2015). This behavior is expected since influenza is an 
enveloped virus and HA inherently reaches the membrane in order to bud out of the cell 
(Szewczyk, Bieńkowska-Szewczyk, & Król, 2014). Previous studies using 
immunofluorescence corroborates our findings showing that HA is localized at the cell 
membrane when influenza VLP expression in Sf9 cells is performed (Latham & Galarza, 
2001). Moreover, expression of HA fused with GFP at the C- terminus in other systems have 
been reported as a strategy to understand VLP formation (Young et al., 2015). However, the 
quenching effects of a trimeric HA-GFP molecule is unknown, and the possibility of quenching 
due to proximity of GFP proteins could affect the fluorescent intensity of the particle. 
3.4.2 Monomeric vs tetrameric fusion partner for M1 
One of the goals of this experiment was to evaluate the use of monomeric and 
tetrameric RFPs as fusion partner of the M1 protein. To this end, 3’ DsRed2 and 3’mKate2 
were tested and their expression analyzed. According to confocal images (Figure 8), the 
DsRed2 variant does not show RFP signal at 24 hpi, nevertheless, this fact does not mean that 
DsRed2 is not been produced during this period of time. The absence of early red fluorescence 
from the 3’ DsRed2 variant may be due to a longer maturation process (Table 5).  Another 
explanation could be the attenuation of fluorescent intensity due to fusion design. Additionally, 
Figure 13 C show a higher ratio level of expression for 3’ DsRed2 at 48 hpi, decreasing to 
lower levels when compared with mKate2 variants at 72 hpi. This phenomenon may be caused 
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by the chromophore maturation of DsRed2. This protein has been engineered from DsRed  and 
has enhanced fluorescence, better solubility and faster maturation (Bevis & Glick, 2002). Even 
though there is no published evidence of DsRed2 undergoing a green fluorescence 
intermediate, it is know that DsRed does (Baird, Zacharias, & Tsien, 2000). The data from this 
experiment suggest that DsRed2 preserves this green intermediate phase, which is not an ideal 
feature since it could disguise the signal from HA-GFP. 
Furthermore, confocal imaging (Figure 8) showed that M1 fusions, with DsRed2 or 
mKate2 at the 3’- terminus, exhibited a high concentration of RFP signal on the nucleus. 
Similar results has been reported by George (2016) and, George & Aucoin (2015). High 
concentration of red expression inside the cells is a sign of low M1 exportation to the 
membrane. This observations support the results presented by Chen, Leser, Morita, & Lamb 
(2007) and Venereo-Sanchez et al. (2016) where higher expression levels of M1 were found 
in the cell pellet rather than in the supernatant when influenza VLPs were produced.  
Table 5. Physical properties of mKate2 and DsRed2 proteins. 
 
3.4.3 Evaluation of M1 fusion sites. 
It is known that M1 plays a critical role in the formation of influenza particles and 
VLPs, however, it has not received as much attention as HA, limiting the information available 
involving their structure or their oligomerization. A complete crystal structure of this molecule 
has not been published and most of the studies focus on truncated forms of the N-terminus 
(Safo et al., 2014). Due to this, an evaluation of different fusion sites on the molecule were 
tested by adding the mKate2 gene on the 3’-terminus, 5’-terminus or in the middle of the M1 













DsRed2 Tetrameric 561 587 0.68 6.5 
(Bevis & Glick, 
2002) 
mKate2 Monomeric 588 633 0.40 > 0.33 
(Shcherbo et 
al., 2009) 
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fusion seems to cluster near the center of the cell. Similarly, 5’ mKate2 variant was in the 
center of the cell, but it looks more spread. In contrast, when mkate2 is placed in the middle of 
M1 gene RFP expression is changed and is observed evenly throughout the cell. This was 
comparable to a baculovirus construct expressing only RFP is used, as shown by George & 
Aucoin (2015).  
Moreover, individual expression levels of genes were analyzed by using the fluorescent 
signal as an indirect measurement (Figure 13). In addition, different normalized ratios of 
expression were obtained for all the M1 variants. The results showed ratio of expression over 
0.75 for the 5’ mKate2 and, 1 for the M mKate2, indicating similar expression levels of RFP 
and GFP. In contrast, the 3’ variant performed with lower ratio levels indicating that RFP had 
higher expression than GFP, an indication of higher level of M1-RFP expression. The previous 
data suggest that the 5’- and 3’-terminus of M1 can be used as fusion site for fluorescent 
protein, without disrupting the M1 protein. Nevertheless, more experiments are needed to fully 
understand the difference on expression levels when M1 fusion proteins are designed. 
3.5 Conclusion 
In this work, the characterization of four different recombinant baculovirus driving the 
expression of HA and M1 fused to a fluorescent protein was performed. Our results showed 
M1 influenza proteins fused to a RFP, either a tetrameric or monomeric, in the 3’ site displayed 
red fluorescence concentrated near the center of the cell nucleus. Moreover, alternative M1 
fusion placing mKate2 in the 5’ site also presented high RFP levels near the center of the cell, 
but not as clustered as the 3’ mKate2 fusion. In contrast, this behavior is disrupted when 
mKate2 is placed in the middle of the M1 gene. Lastly, the difference on ratio of expression 
levels of GFP and RFP were calculated, demonstrating expression differences among the 
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Chapter 4 
Influenza VLP downstream processing 
4.1 Chapter objective 
Downstream processing has the objective to purify a specific molecule from a complex 
sample. Inherent properties of the targeted molecule need to be understood to improve 
purification processes and contaminants removal. Different approaches have been done in the 
past to obtain purified influenza particle, nevertheless, specific downstream procedures are 
needed when working with the BEVS. Baculovirus is considered the main contaminant while 
using the BEVS platform since it has similar physical features when compared with the 
influenza virus. At laboratory scale density gradients are preferred, whereas, chromatographic 
steps are more common for larger scales. Here we test the capacities of sucrose and iodixanol 
density gradient to purify VLPs. This chapter is dedicated to the study of downstream 
processing used on influenza VLP produced using BEVS. The goal of this chapter was to 
determine if VLPs are formed from the expression of M1-fusions and HA-fusions. 
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4.2 Materials and Methods 
4.2.1 Tangential flow filtration (TFF) 
Infected cell cultures were harvested after 72 hours post-infection or when the viability 
was around 70 %. A Stirred Ultrafiltration Cell Model 8050 (Millipore Sigma, Toronto, ON, 
Canada) was used to concentrate influenza VLPs from clarified and filtered (0.2µm filter) cell 
cultures. An Ultracel ultrafiltration disc with a cut-off of 10 kDa (Millipore Sigma, Toronto, 
ON, Canada) was employed to concentrate samples by a factor of 10. Samples were stirred at 
200 rpm under nitrogen at a pressure of 75 psi. Once the desired volume was reached, the cell 
was depressurized, and the sample was stirred for 5 minutes to release all the particles trap on 
the membrane. The sample was stored at 4 °C until next purification step was performed 
4.2.2 Sucrose cushion ultracentrifugation  
TFF concentrated samples were further concentrated by centrifugation using a 25% 
sucrose cushion. This step concentrates, and semi purifies VLP particles by removing low 
density particles. Concentrated VLP samples were layered over 1.5 mL of 25% sucrose 
solution in chilled 1x NTC buffer (1 M NaCl, 0.2 M Tris-HCl pH 7.4, 50 mM CaCl2). A 
Beckman Coulter Optima XPN-100 ultracentrifuge (Beckman Coulter, Mississauga, ON, 
Canada) was used to centrifuge the samples at 26,000 rpm (115, 900 rcf) at 4°C for 2 hours 
using a SW41 Ti Rotor (Beckman Coulter, Mississauga, ON, Canada). The supernatants were 
discarded and VLP pellets were resuspended using pre chilled 1x NTC buffer. Samples were 
shaken at 250 rpm on ice for 30 minutes and pippeted up and down for 10 min. Samples were 
stored at 4°C until next the experiment was performed. 
4.2.3 Sucrose density gradient 
Sucrose density gradients were prepared in a 14x89 pollyallomer centrifuge tubes 
(Beckman Coulter, Mississauga, ON, Canada). The gradient consisted of 6 steps: 10, 20, 30, 
40, 50, 60% sucrose solutions in 1x NTC buffer. 1.5mL of each step was layered using a 
pipette. The resuspended virus pellet was layered at the top of the gradient, above 10% solution, 
and centrifuged. The sample was spun using a SW41 Ti Rotor (Beckman Coulter, Mississauga, 
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ON, Canada) in a Beckman Coulter Optima XPN-100 ultracentrifuge (Beckman Coulter, 
Mississauga, ON, Canada) at 33,000 rpm (186, 700 rcf) for 16 hours and 4°C. 1 mL fractions 
were collected by puncturing the side of the tube. Fractions were weighed, and their density 
calculated. Fractions were stored at 4°C prior to further analysis.  
4.2.4 Iodixanol density gradient 
Iodixanol density gradients were prepared in a 14x89 pollyallomer centrifuge tubes 
(Beckman Coulter, Mississauga, ON, Canada). The gradient consisted of 6 steps, 10, 20, 30, 
40, 50, 60% iodixanol solutions in 1x NTC buffer. 1.5mL of each step was layered using a 
pipette. The resuspended virus pellet was layered at the top of the gradient, above 10% solution, 
and centrifuged. The sample was spun using a SW41 Ti Rotor (Beckman Coulter, Mississauga, 
ON, Canada) in a Beckman Coulter Optima XPN-100 ultracentrifuge (Beckman Coulter, 
Mississauga, ON, Canada) at 35,000 rpm (210,100 rcf) for 2.5 hours at 4°C. 1mL fractions 
were collected by puncturing the side of the tube. Fractions were weighed, and density 
calculated. Fractions were stored at 4°C prior to further analysis. 
4.2.5 Hemagglutination assay 
The presence of influenza VLPs was indirectly determined by the hemagglutination 
assay (Hirst, 1942). Briefly, 50 µL of PBS was added to each well of a round bottom 96-well 
plate, 50 µL of sample was added to the first well. Following mixing, serial dilutions were 
done by adding 50 µL of the previous dilution to produce a row of wells sequentially diluted. 
50 µL of 50% chicken red blood cells (Rockland Immunochemicals Inc. Limerick, PA, USA) 
in PBS was mixed with each dilution. The suspension was allowed to sit at room temperature 
for 2 hours before reading the results. To have hemagglutination the suspension should lack 
aggregation of red blood cells at the bottom of the well. The result of the experiment was noted 
as the number of hemagglutination units (HAU)/50 µL, being the reciprocal of the highest 
dilution in which complete hemagglutination activity was present. In order to have HAU/mL 
the result was multiplied by 20. Hemagglutination units were calculated as detailed in 
Appendix D.  
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4.2.6 Baculovirus quantification using flow cytometry 
The protocol used was adopted from Shen, et al. (2002). Briefly, serial dilutions of viral 
samples were prepared ranging from 10-1 to 10-4. The samples were fixed with a 2% 
paraformaldehyde solution for 1h at 4 ◦C, to obtain a final concentration of 0.02%. The fixed 
samples were then submitted to a freeze-thaw cycle by incubating the samples for 30 min at -
80 ◦C. The samples were permeabilized for 5 min with a solution of 10% Triton X-100 diluted 
in PBS (final concentration of 0.1 % (v/v) was reached). After permeabilization, the samples 
were stained with a diluted solution (5x10-3) of the commercial SYBR® Green I Nucleic Acid 
Gel Stain 10000x (Thermo Fisher, Mississauga, ON, Canada). The stained samples were 
transferred to a 20-well VWR® Digital Dry Block Heater (VWR International, Mississauga, 
ON, Canada) and incubated in the dark for 10 min at 80 °C. After the incubation, the samples 
were ice-cooled and transferred to 5mL polystyrene tube (Bioscience Technology, 
Mississauga, ON, Canada) for flow cytometry analysis.  
Quantification of baculovirus was done with a BD FACSCalibur flow cytometer 
equipped with a 15 mW argon-ion laser emitting at 488 nm. Green fluorescence of baculovirus 
particles was detected using a 530nm band-pass filter. The discriminator was set on the green 
fluorescence (FL1), and the voltage of photomultiplier was adjusted to discriminate between 
the green fluorescence of viral particles and background. Settings and equations can be found 
in Appendix E. Each sample was analyzed three times for 30 seconds at medium flow rate 
(35µL/min). Data were stored and further processed using FlowJo® software (Treestar Inc., 
Ashland, OR, United States). Calibration was done using 3 µm (nominal diameter) polystyrene 
fluorospheres Flow-Set™ (Beckman Coulter, Mississauga, ON, Canada) with a nominal 
concentration of 1x106 fluorospheres/mL. 
4.2.7 Transmission electron microscopy (TEM) 
Electron microscopy was conducted using a Philip CM10 transmission electron 
microscope (TEM). 5 µL of sample was placed onto a sheet of parafilm and a 200 mesh 
formvar-carbon-coated copper grid (Ted Pella Inc, Redding, CA, USA) was placed upside 
down onto the sample drop for 20 minutes. Excess of fluid was removed with filter paper, and 
the grid was placed into a drop of 2% paraformaldehyde in PBS buffer for 5 minutes. The 
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sample was rinsed twice with dH2O. The excess fluid was wicked way with filter paper. For 
the staining process, the grid was placed into a drop of 1% aqueous phosphotungstic acid (PTA) 
pH balanced to pH 7.3 using NaOH solution. After 30 seconds, the sample was removed from 
the drop, and PTA was wicked away with filter paper. The sample was dried overnight prior 
to TEM imaging  
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4.3 Results 
The main goal of downstream processing is to concentrate and purify a desired product. 
The chosen procedures are critical to obtain maximal yield and to remove impurities present 
in the starting material. Supernatants recovered from the infections performed in the previous 
chapter were submitted to the purification process shown in Figure 14. After influenza VLP 
generation, the samples were clarified by centrifugation and filtration using a 0.2 µm 
polyethersulfone (PES) filter. Sample concentration was performed by a two-step process. 
First, clarified samples were concentrated by TFF using a 10 kDa cut-off. Further sample 
concentration was achieved by a 20% sucrose cushion ultracentrifugation. To evaluate each 
step of the process, HA activity and baculovirus quantitation was used. Moreover, supernatant 
from a culture infected with a baculovirus carrying native M1, NA and HA genes was also 
purified using the same procedures to evaluate difference in VLPs, baculovirus concentrations 
and yields.  
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Figure 15 shows baculovirus concentration and HA activity during downstream processing. 
Baculovirus was detected during all the stages for all the samples, whereas, HA activity was 
not detected during the early purification processes for some of the fluorescent constructs. For 
HA activity, the 3’ DsRed2 construct was the only one that was detected throughout the 
purification process. Moreover, 3’ and 5’ mKate2 variants were detected after TFF 
concentration, and, lastly, M mKate2 was detected after sucrose cushion concentration. The 
need for sample concentration was probably due to the low VLP production caused by the 
fluorescent partners interfering in the assembly process. Table 6 shows the yield for each 
purification step for baculovirus and VLPs based on HA activity. Baculovirus purification 
yields for TFF fluctuated from 25 to 50 % among the samples. 5’ mKate2 had the highest yield. 
A range from 8 to 20% was obtained after 20% sucrose cushion purification step for 
baculovirus. In contrast, HA yields were only calculated for 3’ DsRed2 and the non-fluorescent 
variant since only these samples were above the detection limit in the entire process. The non-
fluorescent variant obtained higher HA yields compared with 3’ DsRed2.  
Table 6. HA activity and baculovirus yields. Samples from different purification stages were tested 
for HA activity and baculovirus. The yields were calculated using the clarified supernatant as a 100 % 
recovery 
 % Yield HA 
Purification Step 3’ DsRed2 3' mKate2 5' mKate2 M mKate2 Non-fluorescent 
Clarification 100 100 100 100 100 
Tangential Flow Filtration 24 - - - 48 
Sucrose cushion 16 - - - 24 
 % Yield Baculovirus 
Purification Step 3’ DsRed2 3' mKate2 5' mKate2 M mKate2 Non-fluorescent 
Clarification 100.00 100.00 100.00 100.00 100.00 
Tangential Flow Filtration 24.90 39.04 49.05 45.88 40.49 
Sucrose cushion 11.11 14.31 14.55 7.82 19.55 
-Yields were not possible to calculate since HA concentration was below detection limits 
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Figure 15.  HA activity and baculovirus concentration during VLP purification. Samples from 
different purification stages were tested for the presence of 1) baculovirus using a genome staining 
procedure, and 2) hemagglutination via HA assay. *Samples below detection limit of the experiment 
(80 HAU/mL) 
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4.3.1 Purification of influenza VLPs by density gradient: sucrose and iodixanol.  
Two density gradients were evaluated to purify influenza VLPs. Iodixanol is a iso-
osmotic medium capable of self-generated gradients that has been reported to have little to no 
effect on biological samples (Ford, Graham, & Rickwood, 1994). Iodixanol has been recently 
used to purify adeno-associated virus (AAV) reducing processing time when compared to CsCl 
gradients (Strobel, Miller, Rist, & Lamla, 2015). Moreover, iodixanol has been used to purify 
influenza VLPs produced by insect cells (Thompson et al., 2015). On the other hand, a sucrose 
density gradient is a hyperosmotic environment and is a traditional technique to purify 
influenza VLPs (Krammer et al., 2010). To test the capacities of each gradient, a non- 
fluorescent VLP was used to track the migration pattern of influenza VLPs and baculovirus on 
each gradient. The results are shown in Figure 16. The two gradients showed a different 
migration pattern for HA activity and baculovirus. For the sucrose gradient, HA activity and 
baculovirus were detected from fraction 4 to 12, the highest peak for both was detected at 
fraction 9. Conversely, the iodixanol gradient displayed a different migration pattern, having 
higher concentrations in earlier samples. HA activity was detected from fractions 2 to 9, having 
higher concentrations in fractions 4 and 5 with equal levels. Baculovirus was found from 
fractions 1 to 9, and in fraction 12. Baculovirus was not detected for fractions 10 and 11. The 
highest baculovirus peak was detected in fraction 4. Furthermore, the density values where the 
HA activity and baculovirus were detected differs between the gradients. For the sucrose 
gradient, the density of the samples where HA and baculovirus were detected showed values 
from 1.09 to 1.24 mg/mL, the peak being at 1.17 mg/mL. In contrast, iodixanol fractions 
containing HA activity possess a density from 1.01 to 1.20 mg/mL, with higher concentrations 
gathering at 1.06 to 1.09 mg/mL. Baculovirus was found in densities of 0.99 to 1.20 mg/mL, 
and at 1.27 mg/mL. The highest concentration of baculovirus was detected at 1.06 mg/mL. 
These results demonstrate that density gradients do not possess the resolution capacity to 
properly purify VLPs and baculovirus.  
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Figure 16 Purification profiles of density gradients. A concentrated sample of influenza VLPs was 
split and centrifuged in different density gradients. Profile migration pattern for A) sucrose gradient 
and B) iodixanol gradient 
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4.3.2 Purification of fluorescent VLPs: sucrose density gradient 
Purification of fluorescent influenza VLPs was performed via sucrose density gradient. 
Fractions of 1 mL were collected and analyzed for HA activity, baculovirus and through TEM 
imaging. Figure 17 show the different migration profiles obtained from each sample. 
Moreover, Table 7 shows detailed information of the profiles acquired. The results show lower 
HA activity levels for “fluorescent” VLP fractions when compared to non-fluorescent VLP 
values. Overall, the non-fluorescent VLP construct had an HA activity 16 to 36 times higher 
compared with the fluorescent constructs. Conversely, baculovirus concentrations were similar 
for all the samples in the highest peak (Table 7). Profile HA activity and baculovirus 
distribution, based on fraction density was also analyzed. Density migration patterns presented 
in Table 7 exhibit similar density ranges for HA and baculovirus for all the samples. 
Furthermore, higher concentration of HA activity was found at the same fraction, or close to 
the fraction containing higher baculovirus concentrations. It is still debatable if the changes in 
density values are due to new properties of the fluorescent influenza particles or due to 
sampling variability.  
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Table 7. Purification comparison among fluorescent variants. Concentrated samples of fluorescent 
influenza VLP variants were purified via sucrose density gradient. The results can be shown below. 
HA activity 
Sample Density range/ highest peak 
(mg/mL) 
Highest peak (Fraction) HA activity (HAU/mL) 
3’ DsRed2 (1.18 - 1.21) 1.21 9 160 
3’ mKate2 (1.16 - 1.18)1.18 9 160 
5’ mKate2 (1.13 - 1.18) 1.15-1.18 9 320 
M mKate2 (1.19) 1.19 9 160 
Non-
fluorescent VLP 
(1.09 - 1.24) 1.17 9 5120 
Baculovirus 
Sample Density range/ highest peak 
(mg/mL) 
Highest peak (Fraction) Viral particles at 
highest peak (viral 
particles/mL) 
3’ DsRed2 (1.15- 1.20) 1.18 8 2.00E+09 
3’ mKate2 (1.02 - 1.05/1.12 - 1.18) 1.16 8 7.56E+09 
5’ mKate2 (1.00 – 1.23) 1.18 9 3.78E+09 
M mKate2 (1.02 – 1.23) 1.19 9 1.25E+09 
Non-
fluorescent VLP 
(1.12-1.24) 1.17 9 4.23E+09 
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Figure 17   Purified migration profiles of sucrose density gradients. Migration profile for  
A)3' DsRed2, B)3' mKate2, C) 5' mKate2 and D) M mKate2 
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4.3.3 Viral particle visualization 
To obtain visual confirmation of viral particles, TEM imaging was performed on 
purified samples. For each genetic variant, the fraction with the highest HA activity was used 
for TEM imaging. Figure 18 shows images of the purified fractions after sucrose gradient. 
Baculovirus was detected in all the purified samples imaged. Influenza VLPs were only 
observed on the non-fluorescent variant (Figure 18 E). These results and in accordance with 
our other findings and confirms the low presence of “fluorescent” influenza VLPs. 
Furthermore, lack of visual confirmation could also indicate absence of VLP particles. It is 
possible that the genetic modifications performed to influenza genes disrupt the VLP assembly 
process. 
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Figure 18. TEM imaging of purified samples. A)3’ DsRed2 fraction 8. B) 3’ mKate2 fraction 8. C) M 
mKate2 fraction 9. D) 5’ mKate2 fraction 9 and E) non-fluorescent fraction 9. Black arrows point at 
baculovirus, white arrows point at influenza VLPs 
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4.4 Discussion 
4.4.1 Downstream processing of fluorescent influenza particles 
In this chapter, isolation of influenza like particles derived from influenza-fusion 
proteins was attempted. A series of downstream processing steps were performed and samples 
along the way were analyzed to estimate process yields for influenza VLPs and baculovirus. 
The results gathered during concentration steps indicated lower HA concentrations for 
fluorescent variants, while preserving comparable baculovirus concentration when compared 
to non-fluorescent constructs (Figure 15). A decrease in HA concentration could be caused by 
the fusion of the fluorescent partner on the influenza genes, either HA or M1. In the past it has 
been shown that adding eGFP at the C terminus of the HA0 proteins sequence of H5 does not 
disrupt VLP formation when expressed in Nicotiana benthamiana (Young et al., 2015). 
Nevertheless, there is a lack of information related to the effects of designing M1 fusions. It is 
known that M1 mutations are able to cause morphological changes (Burleigh, Calder, Skehel, 
& Steinhauer, 2005; Elleman & Barclay, 2004), but no reports have been made related to M1 
fusions on either 3’- or 5’- terminus, and how these changes could affect viral assembly. Since 
M1 is the most abundant protein in the influenza virus, it is believed that M1 fusions may cause 
low VLP formation by partially disrupting the viral assembly process.  
4.4.2 Difference on density gradients 
The use of density gradients to purify influenza virions has been a technique used for 
the past century, and it has proven the capacity to isolate influenza particles from complex 
samples such as allantoic fluid from eggs. In addition, different density gradients have been 
used to isolate influenza particles such as cesium chloride (Barry, 1960) as well as sucrose 
(Sengbusch, 1971). In this work sucrose and iodixanol density gradients were compared as a 
purification step for influenza VLPs. Figure 16 shows a different migration pattern for each 
gradient, resulting in purification at different density values. Difference in density band for 
influenza virus has been previously documented when different reagents are used to prepare 
the density gradient (Table 8). The change in density may be due to inherent properties of the 
gradients, sucrose being hyperosmotic, whereas, iodixanol is iso-osmotic. Moreover, slight 
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variability in viral density bands when using the same density gradient could be the result of 
different handling and recovery techniques.  
Table 8. Comparison of density band for influenza virus in different density gradients. 
Density gradient Density band (mg/mL) Reference 
Cesium chloride 1.25 (Barry, 1960) 
Sucrose 1.17 - 1.18 (Sengbusch, 1971) 
Iodixanol 1.06 - 1.09 From this chapter 
 
4.4.3 Baculovirus and influenza VLPs purification 
One of the main concerns when producing influenza VLPs using the BEVS is the 
generation of baculovirus as a side product of the platform. Due to intrinsic similarities 
between baculovirus and influenza, such as similar size and the composition of their lipid 
membrane, specialized purification steps are needed to separate these two viruses. As seen in 
Figures 17 and 18, purified fractions from density gradient containing high HA activity 
possess a high baculovirus content. The lack of resolution power from density gradients is a 
major issue when quantification of influenza particles is required. Previous studies have shown 
that baculovirus is able to display HA molecules on their membrane (Yang et al., 2007). This 
phenomenon is triggered by the enveloped nature of both viruses and may cause noise for HA 
quantification. Given that the HA assay is an indirect quantification of VLPs based on HA 
activity, high levels of baculovirus displaying HA on their surface is not desired. In order to 
separate baculovirus and influenza VLPs other methodologies are needed. Other purification 
procedures including multiple chromatographic steps have been shown in the literature 
(Morenweiser, 2005; Peixoto et al., 2007). Influenza VLPs in insect cells have been purified 
by ion exchange chromatography (IEX) and size-exclusion chromatography (SEC) (Carvalho 
et al., 2016). It has been shown that IEX is able to reduce baculovirus content in an influenza 
VLP sample (GE Healthcare Life Sciences, 2011).   
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4.4.4 Conclusions 
In this chapter a proposed downstream process to purify fluorescent influenza VLPs 
was studied. Bioprocessing characterization of 4 fluorescent influenza VLPs is shown. Each 
purification step of the process was evaluated by quantifying HA activity and baculovirus 
presence. Furthermore, migration patterns of influenza VLPs and baculovirus particles were 
characterized for sucrose and iodixanol density gradient. Our results show that the 
aforementioned methodologies lack enough resolution to separate baculovirus and influenza 
VLPs. To improve the bioprocess shown in this chapter, additional chromatographic steps are 
recommended. The use of size exclusion and ion exchange chromatography are two procedures 
that have showed to reduce baculovirus contamination. Furthermore, the development of 
specific methods to identify the presence of VLPs are needed.  
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Chapter 5 
Flow cytometry analysis of purified Influenza VLPs 
5.1 Chapter objective 
 
Flow cytometry is a technique that offers the analysis of multiple factors of single 
particles. It is known that the detection limit of a conventional flow cytometer is around 300-
500 nm (Steen, 2004). Nevertheless, there have been studies showing the study of different 
nano-sized biological molecules (>100 nm) such as vesicles (Morales-Kastresana et al., 2017; 
van der Vlist, Nolte-’t Hoen, Stoorvogel, Arkesteijn, & Wauben, 2012) and viral particles 
(Brussaard, 2009; Gaudin & Barteneva, 2015).  Previous studies have shown that conventional 
flow cytometers do not always possess enough resolution power to distinguish between noise 
and small particles. Moreover,  it has been shown that in order to detect nano-sized biological 
samples additional preparation steps are needed, which may include staining the genome of a 
virus (Brussaard, 2009) or labeling particles with fluorescent antibodies (Hoen et al., 2012). 
The work presented here showcases the use of flow cytometry to try and detect nano-sized 
fluorescent particles. The goal was to detect fluorescent influenza virus-like particles based on 
their inherent properties without additional staining or fluorescent conjugations. 
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5.2 Materials and Methods 
5.2.1 Data acquisition and processing 
A BD FACSCalibur flow cytometer Pro (BD Biosciences, Mississauga, ON, Canada) 
equipped with a 15 mW argon-ion laser emitting at 488 nm was used to analyze the samples. 
Flow cytometry parameters were optimized by using NTC buffer and PBS as negative controls. 
A log scale was used to collect FSC, SSC, FL1 and FL3 signals with voltages set at E01,474, 
750 and 628 respectively. Moreover, TetraSpeck™ Fluorescent Microspheres (Thermo Fisher, 
Mississauga, ON, Canada) 100 nm at a concentration of 2x1010 beads/mL, and 500 nm beads 
at concentration of 1.6x108 beads/mL were used to determine particle distribution.  
Fractions purified by sucrose density gradient were used in the analysis of the 
fluorescent properties (see Chapter 4). Samples were prepared as follows: 100 µL of purified 
sample was diluted in 900 µL NTC buffer before flow cytometry data acquisition. Each sample 
was run in duplicate at medium flow rate (35 µL/min) for 30 seconds. In addition, serial 
dilutions of purified samples were performed. The results were acquired using CellQuest Pro 
(BD Biosciences, Mississauga, ON, Canada) and analyzed with FlowJo (Treestar Inc., 
Ashland, OR, United States) software.  
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5.3 Results 
5.3.1 Limit of detection and particle distribution 
Detection of nano-sized particles was performed by determining the limit of detection 
of the flow cytometer. Settings were optimized to reduce noise using NTC buffer and PBS 
filtered using a 0.2 µm filter as negative controls (Figure 19 A). From this analysis a 
population was gated, Noise gate, which was noise detected in the SSC vs FL1 plot. The events 
outside the Noise gate were used to analyze nano-sized particles. Fluorescent beads of known 
size were used as reference. It was found that events corresponding to reference beads of 100 
nm and 500 nm were detected outside Noise gate (Figure 19 B). Single channel analysis 
(Figure 19 C) showed an overlap between 100 nm and 500 nm beads on FSC signal. 
Additionally, SSC and FL1 had a better resolution power to distinguish particles of different 
sizes compared with FSC and FL3.  
Serial dilutions of fluorescent beads were performed to detect the decrease in events 
and changes in FL1 signal (Figure 20). A decrease in counts for 500 nm beads was detected, 
while maintaining a constant geometric mean. This behavior is expected when analyzing single 
events, and coincidental events are not detected. On the other hand, dilution decreased the 
number of events for 100 nm in a non-linear fashion. Furthermore, a decrease in geometric 
mean was detected, and never reached a steady measurement. This is an indication of 
coincidental events. To further study coincidental events, single channel analysis of 100 nm 
using the FL1 channel was performed (Figure 21 A). The results showed that when diluting 
the sample, the population was moving towards the limits of detection of the equipment, 
moving inside the Noise gate. When events inside the Noise gate were evaluated an inverse 
relationship was detected when comparing events corresponding to noise and those of 100 nm 
beads (Figure 21 B).  
  




Figure 19. Noise detection analysis and single channel analysis of nano-sized particles. A) Noise 
detection analysis. NTC buffer (red events) and PBS (blue events) were used to optimized parameters 
and identified the Noise gate (noise detected in SSC vs FL1). B) SSC vs FL1 plot of nano-sized beads 
detected outside the Noise gate, countour lines represent the 5% dispersion of the data. C)Single channel 
analysis of nano-sized beads. The plots show the detection of events corresponding to fluorescent beads 
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Figure 20. Analysis of serial dilutions for 500 and 100 nm reference beads outside Noise gate. A) 
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Figure 21.  Analysis of diluted 100 nm beads. A) Single channel analysis of population corresponding 
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Our observations showed that single particle detection was not achieved, however, with 
higher particle concentrations, less noise was detected. The use of this relationship was not 
appropriate to quantify nano-sized particle since the decrease in events could not be 
categorized as single events. However, this phenomenon was used as an indication to detect 
particle presence. The analysis of populations outside the Noise gate showed general features 
of the sample analyzed.  This approach was used to further study the presence of fluorescent 
particles in purified VLP samples. 
5.3.2 Purified VLP sample analysis. 
Dual-fluorescent and non-fluorescent VLP samples obtained from sucrose density 
gradient purification were assessed by flow cytometry. Figure 22 shows the particle 
distribution of purified samples outside the Noise gate. A new population was gated, named 
Gate 1, and used for further analysis. Figure 23 A shows the number of detected events inside 
Gate 1 and Noise gate of purified fractions. An increase in events inside Gate 1 was observed 
from fraction 5 to 12, with fraction 9 being the sample with the highest events detected. Similar 
trends were detected for all the variants, including the non-fluorescent construct. Furthermore, 
it was found that counts inside Noise gate decreased when an increase in events detected inside 
Gate 1 (Figure 23 A). To evaluate this phenomenon, reference solutions were analyzed 
(Figure 23 B). These solutions were used during the purification process and could have an 
impact on particle detection. However, the results showed that reference solutions possess a 
reduced number of events inside Gate 1.   
 Serial dilutions were performed on fractions number 9 to study the properties of 
purified samples (Figure 24). FL1 and FL3 filter were used to study green and red 
fluorescence, respectively. The results showed a decrease in counts inside Gate 1 when the 
samples are diluted (Figure 24 A). In addition, Green fluorescence signal (FL1) was used to 
detect the presence of HA-GFP in the samples. Figure 24 B shows a decrease in green signal 
when the samples are diluted, this trend was seen for all the fluorescent purified samples. 
However, the non-fluorescent VLP samples maintained a steady green signal. In addition, the 
presence of M1-RFP was evaluated using the red fluorescent signal (FL3). It is expected that 
baculovirus could possess a GFP signal, but no RFP signal, since M1 is the principal protein 
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involved in influenza morphology and is not needed for baculovirus replication. The results 
(Figure 24 C) showed a constant red intensity even when the samples were diluted. The same 
trend was observed for all the samples. Further analysis of the red signal showed that the mode 
of diluted samples was located at the limit of detection (Table 4). In addition, FL1 vs FL3 plots 
do not show a visual indication of differences on the red signal (Appendix F). 
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Figure 22. Density plots of fraction 9 of purified samples outside Noise gate. A) 3’ DsRed2, 
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Figure 23. Analysis of purified fractions and reference solutions. A) Events inside Noise and Gate 1 
of purified samples. B) Reference solutions used during purification process. 
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Figure 24. Analysis of serial dilutions of purified samples fraction9 A) Events detected, B) green 
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Table 9. Geometric mean and mode of red signal (FL3) 
Samples 
 
3' DsRed2 3' mKate2 5' mKate2 M mKate2 Non-fluorescent 
Dilution (1:X) Geometric mean 
5 1.14 1.13 1.14 1.15 1.14 
25 1.13 1.12 1.12 1.13 1.13 
125 1.11 1.12 1.14 1.14 1.13 
625 1.13 1.11 1.15 1.13 1.13 
3125 1.15 1.11 1.11 1.12 1.13 
15625 1.10 1.15 1.13 1.14 1.14 
Dilution (1:X) Mode 
5 1.02 1.02 1.02 1.02 1.02 
25 1.02 1.02 1.02 1.02 1.02 
125 1.02 1.02 1.02 1.02 1.02 
625 1.02 1.02 1.02 1.02 1.02 
3125 1.02 1.02 1.02 1.02 1.02 
15625 1.02 1.02 1.02 1.02 1.02 
 
5.4 Discussion 
Nanoscale detection using flow cytometry is not a trivial task since overlapping noise 
and particles are detected. In addition,  limits of detection vary among different flow 
cytometers, and conventional flow cytometers lack resolution power to distinguish nanoscale 
populations (Bonar & Tilton, 2017). Moreover, inherent properties do not always allow 
appropriate particle identification due to their small size and lack of high fluorescence 
intensity. Generation of nanoscale biomolecules with inherent fluorescence could increase the 
intensity of signal detected enabling proper particle identification without further sample 
processing such as fluorescent labelling (van der Vlist et al., 2012).  
5.4.1 Nanoscale particle detection. 
Assessment of nano-sized particles using the FACSCalibur flow cytometer was 
performed using fluorescent beads of known size as controls. 500 and 100 nm beads were 
detected using the optimized parameters gating out signal noise (Figure 19 B and C). In our 
work we showed that the FSC signal of reference beads overlap, whereas SSC and FL1 allowed 
for better resolution of nano-sized beads (Figure 19 C). Similar results were found by Nolan 
& Stoner (2013) when 100 and 500 nm beads were used to evaluate the capacities of the BD 
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FACSCalibur flow cytometer. Their results showed that single channel analysis of SSC and 
FL2 provides better resolution when detecting small-sized particles. Serial dilutions of 
reference beads were used to distinguish between single events and coincidental events 
(Figure 20). It is known that high concentration of nanoscale particles causes coincidental 
events which can lead to poor data acquisition (Morales-Kastresana et al., 2017). Single events 
were detected for the 500 nm reference beads, which showed a linear decrease in number of 
events detected while maintaining a constant fluorescent signal. On the other hand, serial 
dilution of 100 nm beads exhibited a decrease in fluorescent signal, an indication of 
coincidental events. In addition, Figure 21 A shows how the single channel histogram of FL1 
changed in intensity and number of counts when diluting the beads, not reaching and steady 
value. This behavior was an indication of fluorescent beads located inside the Noise gate. 
5.4.2 Downstream detection of VLP 
Our findings indicate that flow cytometry could be used to detect particle presence of 
fluorescent particles, nevertheless, there are still challenges to overcome. The first challenge 
is to increase the resolution to distinguish noise and nanoparticles. Our data showed that 
isolation of VLP particles was not achieved since two populations were expected, one for 
baculovirus, emitting green signal, and other for VLPs, emitting green and red signal. A 
possible solution could be  the use of more sensitive flow cytometers equipped with a more 
powerful laser. Gaudin and Barteneva (2015) have shown detection of Junín virus 
(approximate size between 50 -300 nm) fluorescently labeled using a FACSAria II flow 
cytometer customized with a 488 nm, 300 mW laser. Furthermore, to properly detect VLPs 
and baculovirus, other modifications are needed. It has been shown that detection of small 
particles using the FSC channel with a different angle of scatter light is possible. The use of 
wide-angle (14-25 degrees) instead of conventional FSC (<15 degrees) is preferred and has 
proven better resolution power for nano-sized particles (Hoen et al., 2012). Hoen and 
collaborators (2012) have shown detection of nanosized membrane vesicles using wide-angle 
FSC signal in combination with fluorescent signal in a BD Influx™ flow cytometer. 
Our results indicate an increase in the number of events when data processing was 
performed on the purified fractions (Figure 23 A). The increase of events corresponds to the 
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fractions containing HA activity and baculovirus presence, data shown in Chapter 4. The 
decrease in events detected inside the Noise gate seems to be related to higher particle 
concentration, as seen in Figure 23 A. A similar phenomena was reported by Morales-
Kastresana and collaborators (2017), who showed that a reduction in noise counts is related to 
higher concentration of particles detected. 
Additionally, serial dilutions of fractions 9 were performed to evaluate fluorescent 
capacities of the particles. Figure 24 shows that a distinguishable intensity signals was 
detected by the green channel (FL1). However, since only one population was detected, it is 
still not clear if the events detected represent VLPs and /or baculovirus particles. It is uncertain 
if the source of green fluorescence detected are fluorescent VLPs or fluorescent HA molecules 
displayed on the baculovirus membrane (Yang et al., 2007). Furthermore, red fluorescent 
signal does not provide valuable information to distinguish populations, as seen in Table 4, in 
the system studied.  
5.5 Conclusion 
In this chapter the use of inherent fluorescence of dual-fluorescent particles in 
combination with flow cytometry as a tool to study purified influenza VLP samples was 
discussed. Particle detection was achieved by parameter optimization. Moreover, higher 
particles detection was obtained from samples containing higher HA concentrations and 
baculovirus presence. However, changes in green fluorescent signal (FL1) when samples were 
diluted indicated coincidental events. Furthermore, the red fluorescent signal (FL3) was low 
and on the limits of detection for the equipment, thus not providing any valuable information. 
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Chapter 6 
Conclusions 
6.1 Generation and tracking of fluorescent influenza proteins in insect cells 
Four different recombinant baculovirus driving the expression of different genetic 
constructions were used to evaluate production of a dual-fluorescent VLP expression. Each 
genetic construct was designed to evaluate two red fluorescent protein as fusion partners of 
M1. DsRed2 and mKate2 were fused at the 3’-terminus of M1 and further evaluated. Our 
findings showed that mKate2 is able to generate a detectable red fluorescent signal after 24 
hpi, whereas, DsRed2 required 48 hpi in order to be detected. In addition, DsRed2 also 
increased the green fluorescent signal on early infection stages since the protein undergoes a 
green fluorescent phase of maturation before reaching full maturation. In parallel, three 
different fusion sites were chosen to evaluate the effects of mKate2 fusion on M1. It was found 
that the 5’-terminus and 3’- terminus can be used as fusion site without disturbing RFP 
localized expression near the nucleus. In contrast, the fusion of mKate2 in the middle of M1 
resulted in red expression all over the cell. 
6.2 Downstream processing of fluorescent VLPs 
A laboratory-scale downstream process for fluorescent influenza VLPs was proposed 
and compared with a non-fluorescent influenza VLP. Samples were concentrated by TFF 
followed by an ultracentrifugation using a 25% sucrose cushion. Further purification was 
performed by density gradient. Sucrose and iodixanol density gradients were compared to 
purify non-fluorescent VLPs. The results show a difference between gradients with respect to 
where HA activity and baculovirus have their highest concentration. The highest concentration 
of HA activity and baculovirus was determined at 1.17 mg/mL for sucrose, whereas, for 
iodixanol was in a range of 1.06 to 1.09 mg/mL. Moreover, fluorescent VLP samples purified 
by sucrose density gradient showed similar migration patterns when compared to non-
fluorescent VLPs. Based on our results, the proposed purification process does not fully purify 
influenza VLPs, since baculovirus is largely what is being detected. 
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6.3 Flow cytometry analysis of purified VLPs 
Flow cytometry was used to detect particles in purified samples. Parameters 
optimization and noise caused by the equipment was assessed using NTC buffer. Nano-sized 
particle detection was evaluated by running fluorescent beads of known sizes. It was found 
that 500 nm dilution were detected as single particle events, whereas, 100 nm dilutions present 
coincidental events. Moreover, purified samples were analyzed to study their fluorescent 
properties. Our finding showed the presence of particles with green fluorescent signal.  It was 
found that purified samples of fluorescent constructs decreased when the samples were diluted. 
Moreover, non-fluorescent VLP possessed a consistent green signal 
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Chapter 7 
Recommendations 
The following recommendations will focus on three main problems: increase of VLP 
released to media, further sample purification to reduce baculovirus contamination, and 
enhancement of detection in flow cytometry. 
 The use of complementary controls to further understand the VLP assembly process 
are needed. A strategy will be the use of a recombinant baculovirus driving the expression of 
a native M1 gene. This construct could be use in co-infection experiments along with the 
genetic construct used in this work to further study the impact of M1 fusions on VLP assembly. 
Similarly, co-infections using single recombinant baculovirus carrying a single native or 
fluorescent influenza gene can be used to control the expression levels of each gene. Moreover, 
the combined expression of native M1 and fluorescently fused M1 could increase the stability 
of VLP formation.   
To reduce baculovirus contamination, from a downstream processing point of view, 
additional purification steps based on differential particle features are needed. The additional 
processes should have enough resolution power to properly separate influenza VLPs and 
baculovirus. The inclusion of chromatographic steps to further purify influenza VLPs is a 
possible solution. It has been shown that the combination of ion exchange and size exclusion 
chromatography can considerably reduce baculovirus presence (Carvalho et al., 2016; GE 
Healthcare Life Sciences, 2011). Moreover, Opitz and collaborators (2007) have used affinity 
chromatography to purify influenza viruses produced in MDCK cells. Their work showed the 
screening of different lectins, non-immune origin proteins, as affinity ligands to target 
influenza viruses.  Moreover,  chromatographic steps are highly scalable, which is a desired 
feature to increase industrial production capacity if needed (Sofia et al., 2017; Vicente et al., 
2011). 
On the other hand, improvements in flow cytometry detection are required to fully 
characterize fluorescent VLP particles. One of the possible solutions could be labelling 
influenza VLPs and baculovirus particles with different fluorescent markers to enhance the 
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signal detected. As shown by Nichols and collaborators (1993) influenza virions can be labeled 
by binding fluorescein isothiocyanate (FITC) to the HA and NA influenza proteins. Another 
example is the work performed by Ilushina and collaborators (2014) where they used a lipid-
based technology to label the membrane of influenza particles produced in MDCK cells. 
However, the purpose of labeling influenza particles has been mainly to evaluate the binding 
and internalization of viral particles in cell cultures, but have not been used as a quantification 
technique for flow cytometry 
This approach has been used in the past in order to distinguish small sized populations 
(van der Vlist et al., 2012). Another change could be the use of a specialized flow cytometer 
with enhanced capacities such as a different detection angle of scattered light and/or the use of 
powerful laser (>40 mW). It has been shown that detection of small particles using the FSC 
channel is possible when a different angle for scattered light is used (Bonar & Tilton, 2017). It 
is known that as particle size decreases, light scatter intensity decreases in a nonlinear and 
angle-dependent manner (Nolan & Stoner, 2013).  The use of wide angle (14-25 degrees) 
instead of conventional FSC (<15 degrees) is preferred and has proven better resolution power 
for nano-sized particles (Hoen et al., 2012). Furthermore, it has been shown that using a 
powerful laser (>40mW) is commonly used when small particle detection is required. Flow 
cytometers such as FACSAria II can be customized with a specially powerful laser (300 mW)  
and can be used to this end (Gaudin & Barteneva, 2015)  
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Appendix A 
End Point Dilution Assay (EPDA) 
This technique is based on the Tissue Culture Infectious Dose 50 (TCID50). In order to 
calculate the titer of a baculovirus stock serial dilutions are used to infect a 96-well plate that 
has been previously seeded with Sf9 cells. Then, the dilution where 50 percent of the cells are 
infected is determine and the following equations are used to titer the virus. 
 
Equation AA-1. Proportional response calculation  
𝑃𝐷 =
(𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑗𝑒 𝑟𝑎𝑡𝑒 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛𝑠 𝑛𝑒𝑥𝑡 𝑔𝑟𝑒𝑎𝑡𝑒𝑟 𝑡ℎ𝑎𝑛 50% − 50%)
(% 𝑟𝑎𝑡𝑒 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛𝑠 𝑛𝑒𝑥𝑡 𝑔𝑟𝑒𝑎𝑡𝑒𝑟 𝑡ℎ𝑎𝑛 50%) − (%𝑟𝑎𝑡𝑒 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛𝑠 𝑛𝑒𝑥𝑡 𝑙𝑒𝑠𝑠 𝑡ℎ𝑎𝑛 50%)
 
 
Where PD is the proportional response 
 
Equation AA-2. TCID50 dose calculation 
𝐿𝑜𝑔10(𝑇𝐶𝐼𝐷50) = (𝐿𝑜𝑔 𝑜𝑓 𝑡ℎ𝑒 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛𝑠 𝑔𝑖𝑣𝑖𝑛𝑔 𝑟𝑒𝑝𝑜𝑛𝑠𝑒 𝑔𝑟𝑒𝑎𝑡𝑒𝑟 𝑡ℎ𝑎𝑛 50 % − 𝑃𝐷) 
 





𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑣𝑖𝑟𝑢𝑠 𝑎𝑑𝑑𝑒𝑑
 (0.69) 
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Appendix B 










Figure AB-1. Single fluorescent influenza VLP construct. A) Genetic construct design of single 
fluorescent VLP. A 30 mL Sf9 culture was infected with an MOI of 5. B) shows confocal microscopy 
images of infected Sf9 cells at 48 and 72 hpi.  
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Appendix C 












Figure AC-1. Forward Scatter (FSC) and Side Scatter (SSC) profile of uninfected Sf9 cells. 
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Appendix D 
Calculations used for Hemagglutination Assay (HA Assay) 
This assay is based on the agglutination of red blood cells due to virus presence. The 
HA titer will be the reciprocal of the last dilution without aggregation, the numeric number 
represents the Hemagglutination Units (HAU) per 50 µL. To have HAU/mL this number is 
multiplied by 20. Figures AD-1 shows an example. 
 
 
Figure AD-1 Example calculations for HA Assay 
 














Specifications and calculations used for quantification of 
baculovirus using flow cytometry 
The settings used in the FACSCalibur equipment were: 
 











No Threshold  
Medium flow 35µL/min 
Acquisition time: 30 sec 
 
Calculation of viral particles concentrations using the gated events 
 
Equation AE-1. Viral particles concentration 
𝑉𝑖𝑟𝑎𝑙 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
𝑚𝐿






Cv and Cf: particles counts for viral particles and Flowset, respectively. 
D: Dilution rate of the viral solution 
Vol: volume (µL) of the diluted solution taken for the sample preparation 
1000: final volume of the sample 
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Example of data acquired from flow cytometry and analysis 




Flow set Standard 
Count (FS) Titer (viral particles/mL) 
1 3950 1208 1.66E+07 
2 3654 1072  
3 3754 1146  
Average 3786 1142  
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Appendix F 
















Figure AF-1. Particle distribution of fraction 9 of purified samples. A) 3’ DsRed2, B) 3’ mKate2, C) 
5’ mKate2, D) M mKate2 and E) Non-fluorescent VLP. 
A) B) 
C) D) 
E) 
